 	Median total number of lymph nodes for patients with nodal involvement	Median total number of lymph nodes for patients without nodal involvement	P-value

PCG	13.0 (10–17)*	14.0 (11–18)*	0.654

 	PCG	PSG

Median number of involved lymph nodes	3.0 (1–6)*	2.5 (1–5)*	0.904

	Median total number of lymph nodes for patients with nodal involvement	Median total number of lymph nodes for patients without nodal involvement	P-value

PCG	13.0 (10–17)*	14.0 (11–18)*	0.654

	PCG	PSG

Median numb	3.0 (1	2.5 (	0.9

	Median total number of lymph nodes for patients with nodal involvement	Median total number of lymph nodes for patients without nodal involvement	P-value

er of involved lymph nodes	–6)*	1–5)*	04


	Number of patients	cEPCs(%)	P

Stenosis			0.012

<70%	48	0.052 ± 0.022

≥70%	60	0.091 ± 0.035

Number of intracranial symptomatic arteries			0.578

1	30	0.065 ± 0.024


Sample	CO (μmol·g−1)

Anhydride	Phenol	Carbonyl and Quinone	Pyrone and Chromene

RN1	–	–	380	620

RN1P	–	–	14	140

RN1A	137		1310	–

RN2	–	52	60	800

RN2D5	–	32	–	250

RN2D10	–	–	30	270

Sample	CO (μmol·g−1)

Anhydride	Phenol	Carbonyl and Quinone	Pyrone and Chromene

RN1	–	–	380	620

RN1P	–	–	14	140

RN	13


Indication	Number

Renal impairment and acidosis	20

Renal impairment and hyperkalaemia	0

Renal impairment, acidosis and hyperkalaemia	6

Renal impairment, acidosis and convulsions	2

Renal impairment, acidosis, hyperkalaemia and convulsions	3

Worsening renal function despite conservative measures	5

Worsening renal function and convulsions	1

Renal impairment and pulmonary oedema	1

Renal impairment, acidosis and pulmonary oedema	1

Total	39


Class of agent	Chemical/brand name	Preventive targets

Selective estrogen receptor modulators and other hormonal agents	Tamoxifen	Breast

Arzoxifene	Breast

Acolbifene	Breast

Raxoxifene/Evista®	Breast

Finasteride	Prostate

Nonsteroidal anti- inflammatory drugs	Celecoxib/Celebrex®	Colon, breast, prostate, bladder

Sulindac/Clinoril®	Esophagus, skin

Aspirin

Minerals and micronutrients	Calcium compounds	Colon

Glucocorticoids	Budesonide	Lung

Retinoids	All-trans-retinoic acid tretinoin/Retin-A®	Cervix, esophagus, larynx, lung,

 	9-cis-Retinoic acid alitretinoin/Panretin®	Nasopharynx, oral cavity, ovary

 	13-cis-Retinoic acid isotreninoin/Accutane®

 	4-Hydroxyretinamide, (4-HPR) fenretinide

Class of agent	Chemical/brand name	Preventive targets

Nonsteroidal anti- inflammatory drugs	Celecoxib/Celebrex®	Colon, breast, prostate, bladder

Sulindac/Clinoril®	Esophagus, skin

Aspirin

Minerals and micronutrients	Calcium compounds	Colon

Glucocorticoids	Budesonide	Lung

Retinoids	All-trans-retinoic acid tretinoin/Retin-A®	Cervix, esophagus, larynx, lung,

	9-cis-Retinoic acid alitretinoin/Panretin®	Nasopharynx, oral cavity, ovary

	13-cis-Retinoic acid isotreninoin/Accutane®

	4-Hydroxyretinamide, (4-HPR) fenretinide


	Authors	Publication year	Patient number	Gender	Age	Open (O) or laparoscopic ablation (L)	Symptom related to lymphangioma	Left/right adrenal gland

1	Akand et al. [6]	2013	1	F	44	O	Pain	L

2	Sourial et al. [7]	2013	1	F	52	L	Nihil	L

3	Makni et al. [12]	2012	2	F/M	40/40	O/L	Nihil/pain	2 L

4	Ellis et al. [2]	2011	9	6 F/3 M	28 to 56a	Not precised	5 Nihil/4 pain	6 R/3 L

5	Chien et al. [13]	2008	8	6 F/2 M	31 to 59a	Not precised	4 Nihil/2 pain/1 fever/1 HTNb	4 R/4 L

6	Bettaïeb et al. [8]	2007	1	F	22	Not precised	Pain	L

7	Ates et al. [9]	2005	1	F	26	O	Weakness	R

8	Garcia et al. [10]	2004	1	F	22	Not precised	Pain	R

9	Longo et al. [11]	2000	1	F	30	O	Pain	R

10	Trojan et al. [3]	2000	1	M	40	Not precised	Nihil	R

	Authors	Publication year	Patient number	Gender	Age	Open (O) or laparoscopic ablation (L)	Symptom related to lymphangioma	Left/right adrenal gland

5	Chien et al. [13]	2008	8	6 F/2 M	31 to 59a	Not precised	4 Nihil/2 pain/1 fever/1 HTNb	4 R/4 L

6	Bettaïeb et al. [8]	2007	1	F	22	Not precised	Pain	L

7	Ates et al. [9]	2005	1	F	26	O	Weakness	R

8	Garcia et al. [10]	2004	1	F	22	Not precised	Pain	R

9	Longo et al. [11]	2000	1	F	30	O	Pain	R

10	Trojan et al. [3]	2000	1	M	40	Not precised	Nihil	R


	Mean	Median	Inter-quartile range	Direct cost as % of total cost of illness

Total CNCD sample (n = 475)	1040.82	40	(1000, 0)	56.8 %

Chronic pain conditions (n = 126)	926.92	200	(1268, 0)	51.6 %

Chronic respiratory conditions (n = 98)	623.60	0	(900, 0)	60.8 %

Chronic cardiovascular conditions (n = 95)	1723.99	200	(1600, 0)	54.0 %

Chronic sense organ conditions (n = 65)	465.35	0	(357, 0)	66.4 %

Chronic neuropsychiatric conditions (n = 47)	1465.64	50	(951, 0)	65.2 %

Chronic digestive conditions (n = 42)	929.05	70	(1268, 0)	53.3 %

	Mean	Median	Inter-quartile range	Direct cost as % of total cost of illness

Chronic cardiovascular conditions (n = 95)	1723.99	200	(1600, 0)	54.0 %

Chronic sense organ conditions (n = 65)	465.35	0	(357, 0)	66.4 %

Chronic neuropsychiatric conditions (n = 47)	1465.64	50	(951, 0)	65.2 %

Chronic digestive conditions (n = 42)	929.05	70	(1268, 0)	53.3 %


GenBank accession no.	Gene name	Gene symbol	Fold change (HN2/control)a	Summary function

Highest response to HN2

 BG080773	AMP deaminase 3	Ampd3	4.10	Purine metabolism

 BG066562	proteasome (prosome, macropain) 26S subunit, non-ATPase, 7	Psmd7	3.86	Protein degradation

 C87546	serine/threonine kinase 11	Stk11	3.83	Cell cycle and polarity

 BG086264	polymerase (RNA) II, DNA directed	Polr2	–3.27	RNA synthesis

Neuronal function

 AI850277	neuromedin	Nmu	2.03	Locomotor and stress response

 A1848307	staufen homolog 2	Stauf2	–2.14	RNA transport

 AI847890	proteolipid protein	Plp	–2.16	Myelination

Development

 BG088163	split hand/foot deleted gene 1	Shfdg1	3.08	DNA repair

 AU021923	jagged 1	Jag1	2.61	Oligodendrocyte development

 BG063365	chemokine (C-X-C motif) receptor 4	Cxcr4	2.39	Neural progenitors

 AI847007	NCK-associated protein 1	Nckap1	–2.02	Cell motility

 AI843136	N-myc downstream regulated 2	Ndr2	–2.23	Neural differentiation

Apoptosis control

 C85471	programmed cell death 8	Pdcd8	2.69	Apoptosis control

 BG086831	programmed cell death 4	Pdcd4	2.13	Apoptosis control

 AI853558	tumor necrosis factor receptor superfamily, member 12a	Tnfrsf12a	–2.11	Nuclear factor-kappaB activation

Ubiquitin-proteasome pathway

 BG085363	proteasome (prosome, macropain) 26S subunit, non-ATPase, 11	Psmd11	2.71	Proteasome (19S Lid)

 AI843127	huntingtin interacting protein 2	Hip2	2.11	Ubiqutiin-conjugating enzyme

 AU020960	proteaseome (prosome, macropain) 28 subunit, 3	Psme3	–2.41	Proteasome (20S alpha subunit)

Growth and cell cycle control

 C86021	growth differentiation factor 9	Gdf9	3.61	Cell growth

 AI853288	ras homolog gene family, member U	Arhu	2.33	Signal transduction

 BG072244	calmodulin 1	Calm1	2.13	Cell cycle

 AI843756	calmodulin 2	Calm2	–2.16	Cell cycle

Miscellaneous genes of interest

 AI851097	H1 histone family, member 2	H1f2	–2.36	Chromatin compaction

 AI849019	myelin-associated oligodendrocytic basic protein	Mobp	–2.71	Stuctural components of myelin


	icddr,b service area	Government service area

Cause of death	Male	Female	Total	Male	Female	Total

nate	11.4	.0	11.2			12.6$

# VA with disease symptoma	3217	2729	5,946	3,348	2,819	6,167


Element	Certified value	Amino acids	Glucose	Lipids

[μg/kg]


Type	Number of reads	Percentage (%)

Total unique reads	9,664,154	100

Reads mapping to the transcripts	9,193,054	95.13

Reads mapping to target site	6,916	0.072

Total Number of input cDNAs	77,024	100

Number of covered cDNAs	43,648	56.65


 	Trial	N, inclusion criteria	Dose (dose per fraction)	Outcome

Early hypofractionation trials	Lukka et al. [44]	936GS 6–10	52.5 Gy (2.625 Gy)66 Gy (2 Gy)	40% versus 43% 5-year freedom from biochemical failure

Yeoh et al. [45]	217	55 Gy (2.75 Gy)64 Gy (2 Gy)	53% versus 34% 7-year freedom from biochemical failure

Modern superiority trials	Hoffman et al. [47]	20499% low-intermediate risk	72 Gy (2.4 Gy)75.6 Gy (1.8 Gy)	96% versus 92% 5-year freedom from biochemical failure

Pollack et al. [49]	303GS 6+	70.2 Gy (2.7 Gy)78 Gy (2.17 Gy)	23% versus 21% 5-year biochemical or clinical disease failure

Arcangeli et al. [48]	168GS 7+	62 Gy (3.1 Gy)80 Gy (2 Gy)	85% versus 79% 5-year freedom from biochemical failure

Modern noninferiority trials	Dearnaley et al. [46]	457	57 Gy (3 Gy)60 Gy (3 Gy)74 Gy (2 Gy)	Similar GU and GI toxicity ≥ grade 2 (<5%)

Incrocci [52]	820Intermediate-high risk	64.6 Gy (3.4 Gy)78 Gy (2 Gy)	Worse GI toxicity ≥ grade 2, similar GU toxicity

RTOG 0415 [51]	1101Low risk	70 Gy (2.5 Gy)73.8 Gy (1.8 Gy)	Noninferior biochemical recurrence and overall survival, similar toxicity

PROFIT [53]	Intermediate risk	60 Gy (3 Gy)78 Gy (2 Gy)	Pending

	Trial	N, inclusion criteria	Dose (dose per fraction)	Outcome

Early hypofractionation trials	Lukka et al. [44]	936GS 6–10	52.5 Gy (2.625 Gy)66 Gy (2 Gy)	40% versus 43% 5-year freedom from biochemical failure

Yeoh et al. [45]	217	55 Gy (2.75 Gy)64 Gy (2 Gy)	53% versus 34% 7-year freedom from biochemical failure

Modern superiority trials	Hoffman et al. [47]	20499% low-intermediate risk	72 Gy (2.4 Gy)75.6 Gy (1.8 Gy)	96% versus 92% 5-year freedom from biochemical failure

Pollack et al. [49]	303GS 6+	70.2 Gy (2.7 Gy)78 Gy (2.17 Gy)	23% versus 21% 5-year biochemical or clinical disease failure

Arcangeli et al. [48]	168GS 7+	62 Gy (3.1 Gy)80 Gy (2 Gy)	85% versus 79% 5-year freedom from biochemical failure

Mod	Dearnaley et al. [46]	457	57 Gy (3 Gy)60 Gy (3 Gy)74 Gy (2 Gy)	Similar GU and GI toxicity ≥ grade 2 (<5%)

Incrocci 	820Interme	64.6 Gy (3.4 Gy)	Worse GI toxicity ≥ grade 2, similar GU tox

ern noninferiority trials	[52]	diate-high risk	78 Gy (2 Gy)	icity

RTOG 0415 [51]	1101Low risk	70 Gy (2.5 Gy)73.8 Gy (1.8 Gy)	Noninferior biochemical recurrence and overall survival, similar toxicity

PROFIT [53]	Intermediate risk	60 Gy (3 Gy)78 Gy (2 Gy)	Pending


Implicit review process measure	Acceptable care*	Extremely appropriate care**

	Reviewer 1	Reviewer 2	Reviewer 1	Reviewer 2

Initial data gathering by physician about acute problems	163 (91.6)	151 (84.8)	12 (6.7)	25 (14.0)

Physician integration of information and development of appropriate diagnoses	147 (82.6)	159 (89.3)	10 (5.6)	41 (23.0)

Physician initial treatment plan and orders	117 (65.7)	126 (70.8)	10 (5.6)	26 (14.6)

Physician plan for disposition and follow-up	146 (82.0)	167 (93.8)	10 (5.6)	64 (36.0)

Overall quality of care	136 (76.4)	141 (79.2)	10 (5.6)	22 (12.4)


Score for sorting	KSEARCH	SANS	BLAST

	k = 5	k = 6	k = 7	k = 8	w = 1000	w = 2000

Native	0.51	0.55	0.49	0.44	0.56	0.54

Score for sorting	KSEARCH	SANS	BLAST

	k = 5	k = 6	k = 7	k = 8	w = 1000	w = 2000

Alignment	0.52	0.56	0.49	0.44	0.60	0.62	0.95


Category #	Job title	# of participantsinterviewed

1	Laboratory Manager	3

2	Transfusion Safety Officer	2

3	Lab Technologist (Blood Bank)	9

4	Physicians - Blood Bank	4

5	Physicians - who use blood products	7

6	Hospital Administration	4

7	Hospital PR	1

8	Hospital Risk Management	2

9	Blood Suppliers (CBS, Hema-Quebec)	9

11	MoH (Provincial)	2

13	Recipients of blood products	2

11	Total	45


Age 11

Self-report

Behavior problems

Moods and feelings

Victimisation

Pubertal development

Parent report

Behavior problems

Moods and feelings

Antisocial personality

Autism

ADHD

Age 14

Self-report

Victimisation

ADHD

Pubertal development

Parent report

Victimisation

Autism

Antisocial personality

ADHD

Age 16

Self-report

Behavior problems

Anxiety

Moods and feelings

ADHD

Callous unemotional traits

Autism

Paranoid checklist

Anomalous perceptions

Grandiosity and delusion

Cognitive disorganization

Hedonia

Introvertive anhedonia

Eating problems

Peer victimisation

Sleep

Substance use

Delinquency

Pubertal development

Parent report

Behavior problems

Anxiety

Moods and feelings

ADHD

Negative symptoms

Callous unemotional traits

Autism

Self-report

Age of menarche


Description	Selected study

Critical endpoint	Acute irritation of the eyes and upper airways

	A few (4 out of 27) individuals reacted with additional cough and slight airway obstruction

Source	The Health Council of the Netherlands (2007) (Wieslander et al., 2001)

Species	Healthy human subjects (27)

Exposure regimen	Propylene glycol in aviation emergency training. Exposure to artificial mist generator in short-term inhalation exposure (~1 min)

Concentrations tested (mg/m3)	0, 176-851

Duration of exposure	Average rating on 10 questions before and after 1 min propylene glycol exposure every 30 min for 4 hours

NOAEL (mg/m3)	-

If no NOAEL, then value for LOAEL	Min = 176

	Max = 851

	Mean = 309

Calv;max (mg/m3)	430-603

Source of Calv;max (mg/m3)	1 puff (50 mL [5], 70 mL [6])

MOE1-puff shisha-pen/100% transfer rate	Min range = 0.3-0.4 (~2.5-3x higher than in human study)

	Max range = 1.4-2

	Mean range = 0.5-0.7 (~1.4-2x higher than in human study)


Variables	n (%)

Marital status	single	47 (13.6)

married	259 (75.1)

divorced	37 (10.7)

widow	2 (0.6)

Education	primary	1 (0.3)

vocational	7 (2.0)

secondary	78 (22.6)

higher	259 (75.1)

Place of residence	village	41 (11.9)

town of up to 10,000 residents	10 (2.9)

town of up to 100,000 residents	44 (12.7)

city with more than 100,000 residents	250 (72.5)

Employment status	employed	331 (96.5)

unemployed	12 (3.5)

Number of pregnancies	0	42 (12.2)

1	92 (26.8)

>1	210 (61.0)

Variables	n (%)

Education	secondary	78 (22.6)

higher	259 (75.1)

Place of residence	village	41 (11.9)

town of up to 10,000 residents	10 (2.9)

town of up to 100,000 residents	44 (12.7)

city with more than 100,000 residents	250 (72.5)

Employment status	employed	331 (96.5)

unemployed	12 (3.5)

Number of pregnancies	0	42 (12.2)

1	92 (26.8)

>1	210 (61.0)


Outcomes	Standard Therapy (n = 32)	Acupuncture (n = 34)	p*

Primary outcomes

VAS

Mean VAS score at baseline (SD)	8.02 (1.69)	7.81 (1.48)	0.6

Mean VAS score after therapy (SD)	3.89 (2.38)	2.96 (1.84)	0.08

Mean change in VAS score (SD)	4.12 (2.29)	4.85 (1.87)	0.12

Response rate (>=2 VAS units decrease), %	81.6	89.2	0.8

Secondary outcomes

McGill score

Mean McGill score at baseline (SD)	2.32 (1.05)	2.38 (1.12)	0.8

Mean McGill score after therapy (SD)	0.99 (0.69)	0.99 (0.73)	0.9

Mean change in McGill score (SD)	1.32 (0.85)	1.33 (0.88)	0.9

Post-herpetic neuralgia at 3 months, %	48.4	46.8	0.9

Post-herpetic neuralgia at 6 months, %	33.3	29.0	0.7

Post-herpetic neuralgia at 12 months, %	10.3	3.6	0.3

Mean AUC during follow-up (SD)	199(136)	173(141)	0.5

Outcomes	Standard Therapy (n = 32)	Acupuncture (n = 34)	p*

Primary outcomes

VAS

Mean VAS score at baseline (SD)	8.02 (1.69)	7.81 (1.48)	0.6

Mean VAS score after therapy (SD)	3.89 (2.38)	2.96 (1.84)	0.08

Mean change in VA	4.12 (2.		0.1

Outcomes	Standard Therapy (n = 32)	Acupuncture (n = 34)	p*

S score (SD)	29)	4.85 (1.87)	2

Response rate (>=2 VAS units decrease), %	81.6	89.2	0.8

Secondary outcomes

McGill score

Mean McGill score at baseline (SD)	2.32 (1.05)	2.38 (1.12)	0.8

Mean McGill score after therapy (SD)	0.99 (0.69)	0.99 (0.73)	0.9

Mean change in McGill score (SD)	1.32 (0.85)	1.33 (0.88)	0.9

Post-herpetic neuralgia at 3 months, %	48.4	46.8	0.9

Post-herpetic neuralgia at 6 months, %	33.3	29.0	0.7

Post-herpetic neuralgia at 12 months, %	10.3	3.6	0.3

Mean AUC during follow-up (SD)	199(136)	173(141)	0.5


Predictor	Odds Ratio	95% Confidence Interval

Age	0.97	0.95	1.00*

Education	0.93	0.87	1.01

Services	0.98	0.84	1.14

Partner support	0.88	0.80	0.97**

Mother support	0.95	0.89	1.01

Father support	0.95	0.88	1.02

Weeks pregnant	1.01	0.99	1.02

Single vs. married/living together	0.93	0.68	1.28

Informal housing vs. formal	1.04	0.72	1.49

Unemployed vs. employed	1.09	0.76	1.56

HH income < R2000 p/m	1.52	1.15	2.01**

No income baby father	1.20	0.78	1.83

Tobacco use	1.33	0.67	2.65

Alcohol use	1.22	0.89	1.66

Relationship violence	1.49	1.13	1.96**

Predictor	Odds Ratio	95% Confidence Interval

Age	0.97	0.95	1.00*

Education	0.93	0.87	1.01

Services	0.98	0.84	1.14

Partner support	0.88	0.80	0.97**

Mother support	0.95	0.89	1.01

Father support	0.95	0.88	1.02

Weeks pregnant	1.01	0.99	1.02

Single vs. married/living together	0.93	0.68	1.28

Informal housing vs. formal	1.04	0.72	1.49

Unemployed vs. employed	1.09	0.76	1.56

HH income < R2000 p/m	1.52	1.15	2.01**

No income ba	1.		1.83

Predictor	Odds Ratio	95% Confidence Interval

by father	20	0.78

Tobacco use	1.33	0.67	2.65

Alcohol use	1.22	0.89	1.66

Relationship violence	1.49	1.13	1.96**


Surgical procedure	Vault prolapse	POP-Q III	POP-Q IV

 Sacrospinous fixation 	 4 	 5 	 23

 Anterior colporrhaphy 	 2 	 5 	 23

 Enterocele repair 	 3 	 1 	 20

 Bladder neck suspension 	 1 	 - 	 4

Surgical procedure

Sacrospinous fixation

Anterior colporrhaphy

Enterocele repair

Bladder neck suspension

Vault prolapse	POP-Q III	POP-Q IV

4	5	23

2	5	23

3	1	20

1	-	4


Class	TP rate	FP rate	Precision	Recall	f-measure	ROC area	Accuracy

Migraine	1	1	0.716	1	0.835	0.5	100.00%

Cluster	0	0	0	0	0	0.5	0.00%

Tension	0	0	0	0	0	0.5	0.00%

No headache	0	0	0	0	0	0.5	0.00%

Weighted avg	0.716	0.716	0.513	0.716	0.598	0.5	71.60%

Class	TP rate	FP rate	Precision	Recall	f-measure	ROC area	Accuracy

Weighted avg	0.716	0.716	0.513	0.716	0.598	0.5	71.60%


 	Number of respondents	Percentage (95% CI)

Equipment cost	177	89.4% (85.7-93.1)

Training costs	146	73.7% (68.4-79)

Challenges in training	106	53.5% (47.5-59.5)

Transport times	95	48% (42-54)

Concerns about delaying time to definitive care	90	45.5% (39.5-51.5)

Ultrasound is beyond the scope of practice of providers	76	38.4% (32.6-44.2)

Lack of evidence	76	38.4% (32.6-44.2)

Approval by EMS administration	25	12.6% (8.6-16.6)

Buy-in by other EMS medical directors	21	10.6% (6.9-14.3)

Regulatory factors	29	14.6% (10.4-18.8)

	Number of respondents	Percentage (95% CI)

Equipment c	17	89.4% (

ost	7	85.7-93.1)

Training costs	146	73.7% (68.4-79)

Challenges in training	106	53.5% (47.5-59.5)

Transport times	95	48% (42-54)

Concerns about delaying time to definitive care	90	45.5% (39.5-51.5)

Ultrasound is beyond the scope of practice of providers	76	38.4% (32.6-44.2)

Lack of evidence	76	38.4% (32.6-44.2)

Approval by EMS administration	25	12.6% (8.6-16.6)

Buy-in by other EMS medical directors	21	10.6% (6.9-14.3)

Regulatory factors	29	14.6% (10.4-18.8)


Average hours per month	Programs Reported Resident UseNo. (%)

< 1 h	17 (38)

1–2 h	14 (31)

3–5 h	2 (4)

6–10 h	1 (2)

> 10 h	1 (2)

No response	10 (22)


Antibiotics	Cattle (3 isolates)	Buffalo (1 isolates)	Pig (6 isolates)	Total isolates (10)

R	MS	S	R	MS	S	R	MS	S	R (%)	MS (%)	S (%)

Tr	02	00	01	00	01	00	03	00	03	05 (50)	01 (10)	04 (40)


Economic Quantiles	Tobacco Use Prevalence (TP)	Tobacco Use Quantities (TQ)

Men	Women	All	Men	Women	All

Poorest	26.0	4.1	14.0	12.6	8.4	11.9

Poorer	29.0	3.0	15.5	14.2	12.3	14.0

Middle	30.9	4.0	17.0	14.8	11.1	14.4

Economic Quantiles	Tobacco Use Prevalence (TP)	Tobacco Use Quantities (TQ)

Men	Women	All	Men	Women	All

Richer	28.8	3.0	15.6	15.8	10.1	15.2

Richest	32.7	3.4	17.7	16.5	11.8	16.0

p-value	<0.001	0.179	<0.001	<0.001	0.081	<0.001


rs4880 T > C	Cases, n (%)	Controls, n (%)	OR (95% CI) a	pa


Outcomes	Instrument	t0	t1	t2	t3	t4	t5	t6

Primary endpoint

Overall 2-year survival	Medical log (ongoing assessment)

Secondary endpoints

2-year non-relapse mortality, median (disease-free) survival	Medical log (ongoing assessment)

Quality of life	EORTC QLQ30 / HDC-29 module	X	X	X	X	X	X	X

Fatigue	Multidimensional Fatigue Inventory (MFI)	X	X	X	X	X	X	X

Muscle strength	Isometric and isokinetic strength of representative muscle groups for upper and lower extremity measured at the IsoMed2000®	X			X		X	X

Hand-Held-Dynamometer (isometric)	X	X	X	X	X	X	X

Cardiorespiratory fitness	CPET (VO2peak)	X			X		X	X

	6-min Walk Test	X	X	X	X	X	X	X

Body composition	bioelectrical impedance analysis, weight, height	X	X	X	X	X	X	X

Physical Activity	Accelerometry	X		X	X	X	X	X

Depression	CES-D	X	X	X	X	X	X	X

Distress	NCCN-Distress	X	X	X	X	X	X	X

Locus of control	KKG (German)	X	X	X	X	X	X	X

Cognitive function	Trail-making-test	X	X	X	X	X	X	X

Common side-effects	VAS, every week, later every 3 weeks

Biomarker	Various methods (ELISA)	X	X	X	X	X	X	X

Oxidative stress marker	Analysed in urine samples	X	X	X	X	X	X	X

Others

Socio-demographic factors	Recording of date of birth, education, occupation, familial situation, smoking, alcohol consumption	X					X	X

Medical history	Recording of pre-existing diseases, therapies	X

Treatment data	Conditioning, complications		X

Karnofsky Performance Score	Physician rating	X	X	X	X	X	X	X

Medication (immunosuppression, corticosteroids, analgesics)	Recorded at each visit/phone call on a medication log form	X	X	X	X	X	X	X

Physical activity history	Physical activity in adolescence, pre-diagnosis, during, and after intervention is recorded, including walking, cycling, and sports activities	X			X		X	X

Outcomes	Instrument	t0	t1	t2	t3	t4	t5	t6

	6-min Walk Test	X	X	X	X	X	X	X

Body composition	bioelectrical impedance analysis, weight, height	X	X	X	X	X	X	X

Physical Activity	Accelerometry	X		X	X	X	X	X

Depression	CES-D	X	X	X	X	X	X	X

Distress	NCCN-Distress	X	X	X	X	X	X	X

Locus of control	KKG (German)	X	X	X	X	X	X	X

Cognitive function	Trail-making-test	X	X	X	X	X	X	X

Common side-effects	VAS, every week, later every 3 weeks

Biomarker	Various methods (ELISA)	X	X	X	X	X	X	X

Oxidative stress marker	Analysed in urine samples	X	X	X	X	X	X	X

Others

Socio-demographic factors	Recording of date of birth, education, occupation, familial situation, smoking, alcohol consumption	X					X	X

Medical history	Recording of pre-existing diseases, therapies	X

Treatment data	Conditioning, complications		X

Karnofsky Performance Score	Physician rating	X	X	X	X	X	X	X

Medication (immunosuppression, corticosteroids, analgesics)	Recorded at each visit/phone call on a medication log form	X	X	X	X	X	X	X

Physical activity history	Physical activity in adolescence, pre-diagnosis, during, and after intervention is recorded, including walking, cycling, and sports activities	X			X		X	X


Individual components of global assessment of inflammation	Patients with grade 0, n (%)

 	Difluprednate 0.05% (n=39)	Prednisolone acetate 1% (n=40)

Anterior chamber cell	30 (78.9)	31 (77.5)

Anterior chamber flare	29 (74.4)	28 (70.0)

Corneal clarity	37 (94.9)	36 (90.0)

Conjunctival injection	35 (89.7)	37 (92.5)

Ciliary/limbal injection	39 (100.0)	40 (100.0)

Chemosis	39 (100.0)	39 (97.5)

Hypopyon	39 (100.0)	40 (100.0)

Vitritis	39 (100.0)	39 (97.5)

Wound integrity	39 (100.0)	40 (100.0)

Photophobia	38 (97.4)	38 (95.0)

Lacrimation	39 (100.0)	38 (95.0)

Individual components of global assessment of inflammation	Patients with grade 0, n (%)

	Difluprednate 0.05% (n=39)	Prednisolone acetate 1% (n=40)

Corneal clarity	37 (94.9)	36 (90.0)

Conjunctival injection	35 (89.7)	37 (92.5)

Ciliary/limbal injection	39 (100.0)	40 (100.0)

Chemosis	39 (100.0)	39 (97.5)

Hypopyon	39 (100.0)	40 (100.0)

Vitritis	39 (100.0)	39 (97.5)

Wound integrity	39 (100.0)	40 (100.0)

Photophobia	38 (97.4)	38 (95.0)

Lacrimation	39 (100.0)	38 (95.0)


Material Scan Rate Cathodic Threshold Potential	icorrfw (A/cm2)	CRfw (mm/year)	Ecorrfw (Vvs. SCE)	icorrbw (A/cm2)	CRbw (mm/year)	Ecorrbw (V vs. SCE)	Rp (Ω cm2)

WE43 10 mV/s ET = −1 Vvs. OCP	3.92 × 10−5	5.68 × 10−1	−1.51214	6.67 × 10−5	9.66 × 10−1	−1.5432	276


Ingredients	% of DM

Mix Silage	39.00

Mix Hay	5.00

Barley	18.09

Oats	15.12

Rape Seed Cake	6.48

Rape Seed Meal	2.16

Brewers Grain	2.16

Soybean Meal	3.78

Dried Sugar Beet Pulp	5.40

Wheat Bran	0.81

Mineral Mix1	2.00

Nutrients analysis	% of DM

DM (%)	52.50

CP	17.20

NDF	35.94

Ether extract	3.72

Ash	9.01

Ca	0.89

P	0.46

NEL MJ/kg of DM	6.95

Ingredients

Mix Silage

Mix Hay

Barley

Oats

Rape Seed Cake

Rape Seed Meal

Brewers Grain

Soybean Meal

Dried Sugar Beet Pulp

Wheat Bran

Mineral Mix1

Nutrients analysis

DM (%)

CP

NDF

Ether extract

Ash

Ca

P

NEL MJ/kg of DM


Main nutrients 	Rice porridge	Rice cereal *	Hard-boiled egg yolk

Energy, including dietary fibre (kJ)	158	1537	1450

Protein (g)	0.7	6.8	16.1

Fat (g)	0.1	1.1	31.7

Calcium (mg)	2	6	115

Iodine (ug)	0.8	3.7	127.7

Iron (mg)	0.08	15.5	4.8

Zinc (mg)	0.12	7.8	2.7

Riboflavin (B2) (mg)	0.002	1.9	0.42

Pyridoxine (B6) (mg)	0.01	0	0.33

Vitamin C (mg)	0	33	0

Folate, natural (μg)	1	70	177

Main nutrients	Rice porridge	Rice cereal *

Energy, including dietary fibre (kJ)	158	1537

Protein (g)	0.7	6.8

Fat (g)	0.1	1.1

Calcium (mg)	2	6

Iodine (ug)	0.8	3.7

Iron (mg)	0.08	15.5

Zinc (mg)	0.12	7.8

Riboflavin (B2) (mg)	0.002	1.9

Pyridoxine (B6) (mg)	0.01	0

Vitamin C (mg)	0	33

Folate, natural (μg)	1	70


Variable	Laser	Steel	Total	p-value

Age	 	 	 	0.548

Mean	65.2	67.4	66.3

Range	-	-	34-87

SD	11.5	12.7	12.0

Gender	 	 	 	1.0

Male	20	19	39

Female	3	3	6

Diagnosis	 	 	 	0.463

a) Premalignant

Moderate dysplasia	0	2	2

Severe dysplasia/CIS	6	3	9

b) Invasive SCC

Well differentiated	2	2	4

Moderately differentiated	12	14	26

Poorly differentiated	3	1	4


Cluster description	Codon	Size	Example organism (locus)

Selenocysteine

Formate dehydrogenase α subunit	TGA	45	Escherichia coli (b1474)

Selenide water dikinase	TGA	12	Haemophilus influenzae (HI0200m)

Glycine reductase complex selenoprotein A	TGA	6	Treponema denticola (TDE0745)

Glycine reductase complex selenoprotein B	TGA	6	Treponema denticola (TDE0078)

Heterodisulfide reductase subunit A	TGA	6	Methanococcus jannaschii (MJ1190m)

Coenzyme F420-reducing hydrogenase δ subunit	TGA	5	Methanococcus jannaschii (MJ1190a)

Formylmethanofuran dehydrogenase subunit B	TGA	4	Methanococcus jannaschii (MJ1194m)

Glutaredoxin-like	TGA	3	Carboxydothermus hydrogenoformans (CHY_0740)

Thioredoxin	TGA	3	Geobacter sulfurreducens (GSU3446)

Coenzyme F420-reducing hydrogenase α subunit	TGA	3	Methanococcus jannaschii (MJ0029)

HesB family	TGA	3	Desulfovibrio vulgaris (DVU_1382)

HesB family	TGA	2	Methanococcus maripaludis (MMP0252 + upstream)

Fe-S oxidoreductase	TGA	2	Desulfotalea psychrophila (DP1009)

DsbA-like	TGA	2	Desulfovibrio desulfuricans (Dde_1263 + upstream)

Periplasmic [NiFeSe] hydrogenase large subunit	TGA	2	Desulfovibrio vulgaris (DVU_1918)

Pyrrolysine

Monomethylamine methyltransferase	TAG	7	Methanosarcina acetivorans (MA0144)

Dimethylamine methyltransferase	TAG	7	Methanosarcina acetivorans (MA0532)

Trimethylamine methyltransferase	TAG	6	Methanosarcina acetivorans (MA0528)

Transcriptional regulator, TetR family	TAG	2	Methanosarcina acetivorans (MA2902)

Unknown

Cytochrome c family protein	TGA	2	Geobacter sulfurreducens (GSU2937 + GSU2936)

Hypothetical protein	TAG	2	Geobacter sulfurreducens (GSU2293 + downstream)


	Intention-to-treat analysis	Per protocol analysis

	1 Hz (n = 22)	25 Hz (n = 24)	Group comparison	1 Hz (n = 17)	25 Hz (n = 23)	Group comparison

Treatment period (days)	77.9 ± 25.8	85.7 ± 11.4	p = 0.22	89.0 ± 8.4	87.5 ± 7.5	p = 0.67

Average number of stimulated hours per day	3.42 ± 0.59	3.44 ± 0.61	p = 0.69	3.34 ± 0.62	3.44 ± 0.62	p = 0.51


Variables		Patients	KRAS	NRAS	BRAF

		n	%	n	n	n

Age	≤ 55	14	64	4	1	3

	> 55	8	44	2	0	1

Gender	male	16	73	2	1	4

	female	6	27	4	0	0

Histology	ADC with SRC	3	14	0	0	1

	ADC without SRC	19	86	6	1	3

Calcification	present	3	14	1	0	0

	absent	19	86	5	1	4

Sheldon Stage	I-II	0	0	0	0	0

	IIIA	10	45	2	1	2

	IIIB	7	32	4	0	1

	IIIC	1	5	0	0	0

	IVA	2	9	0	0	0

	IVB	2	9	0	0	1

	IVC	0	0	0	0	0

Mayo stage	I	4	19	1	0	0

	II	10	48	3	1	3

	III	5	24	2	0	0

	IV	2	9	0	0	1

	missing	1

LN or distant meta at diagn.	N0/M0	18	82	6	1	3

	N + / M+	4	18	0	0	1

Initial surgical treatment	partial CE	15	68	5	0	3

	radical CE	5	23	1	0	0

	TURB	2	9	0	1	1

Umbilectomy	yes	11	50	4	0	2

	no	11	50	2	1	2

LND	yes	13	59	3	0	2

	no	9	41	3	1	2

Chemotherapy	yes	6	27	1	1	2

	no	16	73	5	0	2

Progression	local recurrence	2	9	1	1	1

	distant met	2	9	1	0	0

	both	5	23	2	0	1

	no progression	13	59	3	0	2

Variables

Age	≤ 55

	> 55

Gender	male

	female

Histology	ADC with SRC

	ADC without SRC

Calcification	present

	absent

Sheldon Stage	I-II

	IIIA

	IIIB

	IIIC

	IVA

	IVB

	IVC

Mayo stage	I

	II

	III

	IV

	missing

LN or distant meta at diagn.	N0/M0

	N + / M+

Initial surgical treatment	partial CE

	radical CE

	TURB

Umbilectomy	yes

	no

LND	yes

	no

Chemotherapy	yes

	no

Progression	local recurrence

	distant met

	both

	no progression


	Alcohol intake (g/day)

	0	0.1–5	5.1–15	>15

No. of participans	10,153	22,249	11,734	1,097

Age at enrollment (mean)	39.8	39.7	40.5	41.4

Educational attainment >11 years, (%)	46.3	56.3	61.4	61.7

History of breast cancer in mother and/or sister (%)	4.2	4.2	5.3	5.9

Smoking habits (%)

 Never	50.5	43.0	32.0	18.1

 Former	28.2	35.3	40.7	40.7

 Current	21.3	21.7	27.3	41.2

Age at menarche (mean)	12.9	13.0	13.0	13.1

Women with more than 3 children (%)	32.5	27.2	24.0	23.4

Age at first child birth among parous women (mean)	23.5	24.0	24.1	23.8

Total duration of breast feeding (months)	30.9	30.8	30.2	30.3

Ever oral contraceptive use (%)	75.1	85.0	88.2	89.7

Post-menopause (%)	4.4	3.8	4.3	3.7

Body mass index (>25 kg/m2, %)	31.9	24.1	21.1	24.6

	Alcohol intake (g/day)

	0	0.1–5	5.1–15	>15

en with more than 3 children (%)	2.5	.2	0	4

Age at first child birth among parous women (mean)	23.5	24.0	24.1	23.8

Total duration of breast feeding (months)	30.9	30.8	30.2	30.3

Ever oral contraceptive use (%)	75.1	85.0	88.2	89.7

Post-menopause (%)	4.4	3.8	4.3	3.7

Body mass index (>25 kg/m2, %)	31.9	24.1	21.1	24.6


 	Location	Group	IHC grade#	P value*

 	Stroma	Cancer nest	−	+	++	+++	++++

α-SMA	Positive$	ND	Chronic nasopharyngitis (21)	11	7	2	1	0	0.000

NPC (18)	0	4	0	7	7

CD133	Positive	ND	Chronic nasopharyngitis (10)	9	1	0	0	0	0.006

NPC (30)	8	9	9	4	0

VEGFR-2	Positive	ND	Chronic nasopharyngitis (8)	7	1	0	0	0	0.04

NPC (10)	2	5	1	2	0

CD34	Positive	ND	Chronic nasopharyngitis (14)	0	8	6	0	0	0.000

NPC (24)	0	0	3	7	14

CXCR4	Positive	Positive	Chronic nasopharyngitis (6)	0	3	1	2	0	0.041

NPC (11)	0	0	2	4	5

VEGF-A	Positive	Positive	Chronic nasopharyngitis (10)	0	1	5	4	0	0.015

NPC (19)	0	0	2	9	8

SDF-1	ND	Positive	Chronic nasopharyngitis (22)	5	9	5	2	1	0.008

NPC (20)	3	0	7	5	5

	Location

	Stroma

α-SMA	Positive$

CD133	Positive

VEGFR-2	Positive

CD34	Positive

CXCR4	Positive

VEGF-A	Positive

SDF-1	ND

Location	Group	IHC grade#	P value*

Cancer nest	−	+	++	+++	++++

ND	Chronic nasopharyngitis (21)	11	7	2	1	0	0.000

NPC (18)	0	4	0	7	7

ND	Chronic nasopharyngitis (10)	9	1	0	0	0	0.006

NPC (30)	8	9	9	4	0

ND	Chronic nasopharyngitis (8)	7	1	0	0	0	0.04

NPC (10)	2	5	1	2	0

ND	Chronic nasopharyngitis (14)	0	8	6	0	0	0.000

NPC (24)	0	0	3	7	14

Positive	Chronic nasopharyngitis (6)	0	3	1	2	0	0.041

NPC (11)	0	0	2	4	5

Positive	Chronic nasopharyngitis (10)	0	1	5	4	0	0.015

NPC (19)	0	0	2	9	8

Positive	Chronic nasopharyngitis (22)	5	9	5	2	1	0.008

NPC (20)	3	0	7	5	5


Age (years)

Height (cm)

Body fat (%)

Weight (kg)

Body mass index (kg/m2)


	Culture-Gram-PCR resultb

All tests negative	Isolated RT-PCR positive	All tests positive

	(n=329)	(n=20)	(n=75)

Age in years (median, range)	9 (0–64)	11 (0–63)	15 (0–78)

Altered mental status (%)	66 (22.6)	6 (40.0)	47 (66.2)

Deaths (%)	27 (9.1)	2 (10.5)	10 (14.3)


	Male	Female	Total

Cas		p		Cases	n			Cases	n


Specific primer	Primer sequences (5′–3′)

N type DlRans	Forward: AAGGACAGCTCTCATGGCTTTGC

Reverse: TGCCTCCATCACCGACGATGAC

D type DlRans	Forward: TAGTGATCGTCGGCGATGGTGG

Reverse: TGCAGTGTCCCAGCAATAGAAGCG

Fe-SOD	Forward: GGTCAGATGGTGAAGCCGTAGAG

Reverse: GTCTATGCCACCGATACAACAAACCC

EF-1a	Forward: GATGATTCCCACCAAGCCCAT

Reverse: GGGTCCTTCTTCTCAACACTCT


	Increasing ANNV (> 4)

Parameter	PCa (n = 22)	BPH (n = 16)

Age (years)	65*	68.5

tPSA (ng/mL)	8.3	6.8

%fPSA (%)	8.0*$	13.15

Volume (mL)	33.5*	36.5*


Group	Swell degree (mg)	Inhibition rate (%)

Fenli	5.13 ± 0.68	69.15

DE MDTS	5.86 ± 1.76	64.76

Control	16.63 ± 1.57


Workflow	Sequential	Parallel

Preprocess (clipOverlap)	2.82	2.91

SNV: mutationSeq	5.68	5.99

SNV: Strelka	2.60	4.49

CNV: Titan	29.34	36.31

CNV: Sequenza	8.24	9.40

Workflow	Sequential	Parallel

cess (clipOverlap)	2.82	2.91

SNV: mutationSeq	5.68	5.99

SNV: Strelka	2.60	4.49

CNV: Titan	29.34	36.31

CNV: Sequenza	8.24	9.40


Gene Name	Primers

Rbcl (ribulose-1,5-bisphosphate carboxylase/oxygenase: Genbank-KR914695.1)	Rbcl1: ACGAATGTTTACGCGGTGGTCT

Rbcl2: GGTACACCCAACTCCTTAGCA

CrtZ (carotenoid hydroxylase: Genbank-KP866868.1)	CrtZ1: ATCTTCGCCACCTACCTGAG

CrtZ2: CGGGCAGTCCATTGATGATT

LcyB (lycopene beta cyclase: Genbank-AY182008.1)	LcyB1: CTTTGACCCAGCACGACTTG

LcyB2: TTAGGAACTTCTCGCCCTCT

CrtISO (carotenoid isomerase: Genbank-KP780062.1)	CrtISO1: GCACCACTAACCTCATCACA

CrtISO2: CCTTCCAGCAGTCGTCATAA

ZEP (zeaxanthin epoxidase: Genbank-KP780061.1)	ZEP1: TACCTCAACCCTGCTCCTGA

ZEP2: TTCGCCCTTCTCAAGCCTGT

Gene Name	Primers

Rbcl (ribulose-1,5-bisphosphate carboxylase/oxygenase: Genbank-KR914695.1)	Rbcl1: ACGAATGTTTACGCGGTGGTCT

Rbcl2: GGTACACCCAACTCCTTAGCA

CrtZ (carotenoid hydroxylase: Genbank-KP866868.1)	CrtZ1: ATCTTCGCCACCTACCTGAG

CrtZ2: CGGGCAGTCCATTGATGATT

LcyB (lycopene beta cyclase: Genbank-AY182008.1)	LcyB1: CTTTGACCCAGCACGACTTG

LcyB2: TTAGGAACTTCTCGCCCTCT

CrtISO (carotenoid isomerase: Genbank-K	CrtISO1: GCA

Gene Name	Primers

P780062.1)	CCACTAACCTCATCACA

CrtISO2: CCTTCCAGCAGTCGTCATAA

ZEP (zeaxanthin epoxidase: Genbank-KP780061.1)	ZEP1: TACCTCAACCCTGCTCCTGA

ZEP2: TTCGCCCTTCTCAAGCCTGT


Factors	The effects of selection criteria fulfillment and AFP on recurrence-free survival adjusted for

Microvascular invasion	Poor tumor differentiation	Recipient age

HR (95 % CI)	P	HR (95 % CI)	P	HR (95 % CI)	P

Milan criteria and AFP

Within Milan criteria	0.20 (0.08–0.50)	<0.001	0.19 (0.08–0.48)	<0.001	0.18 (0.07–0.44)	<0.001

AFP >100 ng/ml	3.98 (1.87–8.47)	<0.001	3.56 (1.69–7.52)	<0.001	3.46 (1.62–7.41)	0.001

UCSF criteria and AFP

Within UCSF criteria	0.26 (0.12–0.57)	<0.001	0.25 (0.11–0.54)	<0.001	0.23 (0.10–0.50)	<.001

AFP >100 ng/ml	3.83 (1.81–8.12)	<0.001	3.31 (1.55–7.08)	0.002	3.38 (1.58–7.22)	.002

Up-to-7 criteria and AFP


Test	Method

Blood testsAs listed in table 1, plus:

 Collagen C-telopeptide (CTX)Osteocalcin (OC)	Roche Elecsys beta cross-lapsRoche Elecsys 2010Canterbury District Health Board Laboratory

Weight at baseline and 6 months	Tanita electronic scales


	Rule role	Rule example	Location term

Ex. 1	Type disambiguation	IF dead, decaying in term THEN type =Env	dead animal (Host) becomes dead animal (Env)

Ex. 2	Boundary extension	IF nationality before term (Env) THEN include nationality	oil field (Env) becomes German oil field (Env)

Ex. 3	Boundary reduction	IF irrelevant modifier in term THEN delete modifier	infected rodent (Host) becomes rodent (Host)


Rabbit antibody	Neutralization titers	Dog Sera A/Pa	Serological prevalence

3–68	W191R	L198 T	A128T	Arrivala	Posta

3–68	>1024	16	<4	<4	< 4 / 32	14/21c	14/21


	Clients & informal caregivers (n = 28)	Health care providers (n = 20)

Urban (n = 16)	Male	4	0

Female	8	4

Rural (n = 32)	Male	1	1

Female	15	15

Urban (n = 16)	Female	8	4

Rural (n = 32)	Male	1	1

Female	15	15


	Median duration of stay (days) for SARI cases	Median duration in ICU (days) for SARI cases with ICU treatment	Median duration of ventilation (hours) for ventilated SARI cases

Case definition	< 5	5–14	15–34	35–59	60+	all	< 5	5–14	15–34	35–59	60+	all	< 5	5–14	15–34	35–59	60+	all

BCD	4	4	4	6	8	6	3	4	3	3	3	3	100	140.5	78	74	61	69

SCD	4	4	5	8	10	8	3	4	4	5	4	4	118	143	128.5	142	95	104

TCD	4	4	3	4	5	4	2	3	1	1	1	2	44	117	47	41.5	32	37


Gene id	ContiguousE. histolytica DNA region ID	Length (bp)	Location of SNP(s) (bp)

EHI_080100	DS571720	5179	2725-2730

EHI_065250	DS571302	38246	10296-10318

ContiguousE. histolytica DNA region ID	Length (bp)	Location of SNP(s) (bp)

DS571720	5179	2725-2730

DS571302	38246	10296-10318


Antimicrobial agents	MIC range	MIC50	MIC90	Resistance (%)	Susceptible (%)

Cefoperazone–sulbactam	16–256	64	128	85.4	4.2

Ampicillin–sulbactam	16–128	64	128	93.8	0

Piperacillin–tazobactam	128 to >256	>256	>256	100	0

Ceftazidime	32–64	64	64	100	0

Cefepime	32–64	64	64	100	0

Imipenem	1–32	32	32	95.8	2.1

Meropenem	2–32	32	32	95.8	2.1

Amikacin	8 to >128	>128	>128	83.3	16.7

Gentamicin	2–64	64	64	95.8	4.2

Ciprofloxacin	16	16	16	100	0

Levofloxacin	4–32	8	32	91.7	0

Trimethoprim–sulfamethoxazole	1–16	16	16	97.9	2.1

Colistin	1–32	1	2	4.2	93.8

Tigecycline	0.25–2	0.5	1	0	100


Group	Sequence	Repeat times

A1	DYDRYSSALIAA	5

A3	YWTPGYTPSQTE	1

A7	NNSRDTALRWFV	1

A13	GQPKTFLSVSEL	5


No.	Primer’s name	Forward sequence	Reverse sequence	Annealing time and temperature

1	otud4	CCACCTCCTGCAGAACAAAAG	GGGTCTTGGTAAAGGCTCATT	15 s/60 °C

2	cx43 (gja1)	TGCTGCGAACCTACATCATC	CGATGACGTTCAAGGCAAGA	15 s/60 °C

3	sod2	GTCACCGAGGAGAAGTACCA	CTGGTTAGGACAGGCAACAA	15 s/60 °C

4	sod1	GATTCCACGTCCACGAGTTT	CCCGAGAGTGAGATCACAGA	15 s/60 °C

5	tgfb2	AGTACTACGCCAAGGAGGTT	TAGGCGGGATGGCATTTTCC	15 s/60 °C

6	myf5	GGAGACGCCTGAAGAAAGTC	CCGGCAGGCTGTAGTAATTC	15 s/60 °C

7	bdnf	CCCCATGAAAGAAGCAAACG	TACAAGTCCGCGTCCTTACT	15 s/60 °C

8	gapdh	GTTTGTGATGGGCGTGAACC	GTCTTCTGGGTGGCAGTGAT	15 s/60 °C

No.	Primer’s name	Forward sequence	Reverse sequence	Annealing time and temperature

8	gapdh	GTTTGTGATGGGCGTGAACC	GTCTTCTGGGTGGCAGTGAT	15 s/60 °C


Organism	Inpatient	Outpatient	Pediatrics	Missing	Total

Streptococcus species	162	16	19	9	206

Neisseria species	94	11	2	0	107

Haemophilus species	47	2	9	1	59

Staphylococcus aureus	34	1	1	0	36

Escherichia coli	13	7	1	1	22

Other Gram negative	20	2	0	0	22

Other Gram positive	12	0	1	0	13

Enterococcus species	8	0	1	0	9

Acinetobacter species	6	0	2	0	8

ESBL’s Klebsiella pneumoniae	6	1	0	0	7

Klebsiella	7	0	0	0	7

Pseudomonas species	0	0	7	0	7

Total	409 (81.3%)	40 (8.0%)	43 (8.5%)	11 (2.2%)	503 (100%)


Mesencephalon

Most Discriminative Texture Parameters on Patients	p-values (patients)	p-values (controls)	Most Discriminative Texture Parameters on Controls	p-values (controls)	p-values (patients)

Teta4	<0.001*	0.105	S(4,-4)DifVarnc	0.002*	0.519

Teta3	<0.001*	0.020*	S(5,-5DifVarnc	0.004*	0.465

S(5,5)Entropy	<0.001*	0.105	Teta3	0.020*	<0.001*

S(5,5)AngScMom	<0.001*	0.020*	S(5,-5)DifEntrp	0.004*	0.413

S(4,4)AngScMom	<0.001*	0.432	Teta2	0.014*	<0.001*

S(4,4)Entropy	<0.001*	0.322	S(4,-4)DifEnrtp	0.002*	0.372

Teta2	<0.001*	0.014*	S(3,-3)DifVarnc	0.002*	0.160

S(1,-1)DifVarnc	<0.001*	0.375	WavEnLL_s-2	0.027*	0,472


 	Administration	Clearance	Side effects

GLP-1R agonist	Subctaneous	 	Weight loss	Gastrointestinal tract (GIT)

Exenatide	Twice a day, once a week	Renal	+	++/±*

Liraglutide	Once a day	Extrarenal	+	+

DPP-4 inhibitor	Oral	 	→	→

Sitagliptin	Once a day	Renal	→	→

Vildagliptin	Twice a day	Renal	→	→

Saxagliptin	Once a day	Renal	→	→

Linagliptin	Once a day	Extrarenal	→	→

Anagliptin	Twice a day	Renal	→	→

Teneligliptin	Once a day	Extrarenal > renal	→	→

Alogliptin	Once a day	Renal	→	→


MIGS ID	Property	Term	Evidence codea

	Classification	Domain Bacteria	TAS [37]

		Phylum Bacteroidaeota	TAS [3]

		Class Flavobacteriia	TAS [38]

		Order Flavobacteriales	TAS [39]

		Family Flavobacteriaceae	TAS [40]

		Genus Elizabethkingia	TAS [2]

		Species Elizabethkingia meningoseptica	TAS [2]

		Strain Em3	TAS [2]

	Gram stain	Negative	IDA

	Cell shape	Rod	IDA

	Motility	Non motile	IDA

	Sporulation	Non-spore-forming	NAS

	Temperature range	4–40 °C	IDA

	Optimum temperature	37 °C	IDA

	pH range; Optimum	4–10; 8	IDA

	Carbon source	Heterotroph	IDA

	Energy source	Varied; including glucose and mannitol	IDA

MIGS-6	Habitat	Human	NAS

MIGS-6.3	Salinity	Not determined

MIGS-22	Oxygen requirement	Aerobic	NAS

MIGS-15	Biotic relationship	Free-living	NAS

MIGS-14	Pathogenicity	Pathogen	NAS

MIGS-4	Geographic location	Michigan, USA	NAS

MIGS-5	Sample collection time	February, 6, 2016	NAS

MIGS-4.1	Latitude	42° 43′ 57′′ N	NAS

MIGS-4.2	Longitude	84° 33′ 20′′ W	NAS

MIGS-4.4	Altitude	Not reported	NAS

MIGS ID

MIGS-6

MIGS-6.3

MIGS-22

MIGS-15

MIGS-14

MIGS-4

MIGS-5

MIGS-4.1

MIGS-4.2

MIGS-4.4

Property	Term	Evidence codea

Classification	Domain Bacteria	TAS [37]

	Phylum Bacteroidaeota	TAS [3]

	Class Flavobacteriia	TAS [38]

	Order Flavobacteriales	TAS [39]

	Family Flavobacteriaceae	TAS [40]

	Genus Elizabethkingia	TAS [2]

	Species Elizabethkingia meningoseptica	TAS [2]

	Strain Em3	TAS [2]

Gram stain	Negative	IDA

Cell shape	Rod	IDA

Motility	Non motile	IDA

Sporulation	Non-spore-forming	NAS

Temperature range	4–40 °C	IDA

Optimum temperature	37 °C	IDA

pH range; Optimum	4–10; 8	IDA

Carbon source	Heterotroph	IDA

Energy source	Varied; including glucose and mannitol	IDA

Habitat	Human	NAS

Salinity	Not determined

Oxygen requirement	Aerobic	NAS

Biotic relationship	Free-living	NAS

Pathogenicity	Pathogen	NAS

Geographic location	Michigan, USA	NAS

Sample collection time	February, 6, 2016	NAS

Latitude	42° 43′ 57′′ N	NAS

Longitude	84° 33′ 20′′ W	NAS

Altitude	Not reported	NAS


Included trials	Selective head cooling	Whole body cooling

	Gunn 1998	Gluckman 2005	Shankaran 2002	Shankaran 2005	Eicher 2005

Design	RCT	RCTMulticenter	RCTMulticenter	RCTMulticenter	RCTMulticenter

Number of participants	26	234	19	208	65

Gestation	≥ 37 wks	≥ 37 wks	≥ 36 wks	≥ 37 wks	≥ 35 wks

Inclusion criteria (details see Table 2)	Asphyxia and moderate to severe HIE	Asphyxia and moderate to severe HIE	Asphyxia and moderate to severe HIE	Asphyxia and moderate to severe HIE	Asphyxia and HIE

Target temperature treatment group (°C)	34.5–35.5 (n = 6)34.0–35.0 (n = 7)Not analyzed:36.0–36.5 (n = 6)35.5–35.9 (n = 6)	34.0–35.0	34.5	33.5	32.5–33.5

Target temperature control group (°C)	36.8–37.2	36.5–37.5	36.5	36.5–37.0	36.5–37.5

Site of temperature probe	Rectal	Rectal	Esophageal	Esophageal	Rectal

Average age at start of cooling (min)	294	330	318	302	120

Duration of cooling (h)	48–72	72	72	72	48

Cooling device	Servo-controlled cooling cap	Servo-controlled cooling cap	Two servo-controlled cooling blankets	Two servo-controlled cooling blankets	Ice bags followed by one servo-controlled cooling blanket

Primary outcome	Adverse events	Composite of death/severe disability	Adverse events	Composite of death/moderate or severe disability	Adverse events

Latest follow-up (months)	18	18	Follow-up not reported	18–22	12

Follow-up tools	Bayley II	Bayley IIGMF	-	Bayley IIGMF	Bayley IIVineland

Included trials	Selective head cooling

	Gunn 1998

Design	RCT

Number of participants	26

Gestation	≥ 37 wks

Inclusion criteria (details see Table 2)	Asphyxia and moderate to severe HIE

Target temperature treatment group (°C)	34.5–35.5 (n = 6)34.0–35.0 (n = 7)Not analyzed:36.0–36.5 (n = 6)35.5–35.9 (n = 6)

Target temperature control group (°C)	36.8–37.2

Site of temperature probe	Rectal

Average age at start of cooling (min)	294

Duration of cooling (h)	48–72

Cooling device	Servo-controlled cooling cap

Primary outcome	Adverse events

Latest follow-up (months)	18

Follow-up tools	Bayley II

Selective head cooling	Whole body cooling

Gluckman 2005	Shankaran 2002	Shankaran 2005	Eicher 2005

RCTMulticenter	RCTMulticenter	RCTMulticenter	RCTMulticenter

234	19	208	65

≥ 37 wks	≥ 36 wks	≥ 37 wks	≥ 35 wks

Asphyxia and moderate to severe HIE	Asphyxia and moderate to severe HIE	Asphyxia and moderate to severe HIE	Asphyxia and HIE

34.0–35.0	34.5	33.5	32.5–33.5

36.5–37.5	36.5	36.5–37.0	36.5–37.5

Rectal	Esophageal	Esophageal	Rectal

330	318	302	120

72	72	72	48

Servo-controlled cooling cap	Two servo-controlled cooling blankets	Two servo-controlled cooling blankets	Ice bags followed by one servo-controlled cooling blanket

Composite of death/severe disability	Adverse events	Composite of death/moderate or severe disability	Adverse events

18	Follow-up not reported	18–22	12

Bayley IIGMF	-	Bayley IIGMF	Bayley IIVineland


Candidate Biomarker	Comparison	Difference	Lower CI	Upper CI	Q-value

CEA	Malignant/Non-malignant	1.97	1.08	2.85	0

CEA	Malignant/Healthy	2.11	1.02	3.19	0

IL.8	Malignant/Healthy	1.22	0.14	2.31	0

Prolactin	Non-malignant/Healthy	1.1	0.02	2.19	0.04


Health professional/service	Communications sent out	Communications received

6	Oncologist	0	1

7	Psychologist	0	1

9	Neurosurgeon	5	1

16	Primary nurse, Oncology	0	0

23	Family Physician	0	1

30	Pediatrician/Palliative Care	0	0

36	Oncologist	0	1

38	Oncologist	0	2

42	Pediatrician/Palliative Care	0	1

44	Neurosurgeon	0	3

47	Neurosurgeon	3	0

78	Canuck Place	3	0

	Mean	0.92	0.92


 	Free attention (FA)	 	Attention to the right (AR)	 	Attention to the left (AL)

P	G	P	G	P	G

Mean	1.04	0.67	 	2.18	2.63	 	2.31	1.71

S.D	1.22	0.98	 	1.70	2.88	 	2.06	2.21

Mann-Whitney Test (P X G)	0.288	 	 	1.00	 	 	0.396


	Magnetic Detection	Microbiological Tests

Anti-Streptococcus agalactiae	Anti-GB Streptococci

Mastitic Milk Isolates		Correctly Identified		Correctly Identified		Correctly Identified

	n	n	%	MI 1	n	%	MI	n	%	MI

S. aureus	1	0	0.0	0	1	100.0	0	0	0.0	1

S. agalactiae	13	7	70.0	3	2	25.0	6	13	100.0	0

S. uberis	11	3	33.3	6	5	62.5	3	8	72.7	3

Streptococcus spp.	4	0	0.0	3	2	50.0	2	1	25.0	3

Staphylococcus spp.	2	0	0.0	0	1	50.0	1	2	100.0	0

Enterococcus spp.	7	3	75.0	1	1	33.3	2	0	0.0	7

Escherichia coli	3	0	0.0	1	1	50.0	1	3	100.0	0

Yeasts	3	0	0.0	2	1	100.0	0	2	66.7	1

Prototheca	2	0	0.0	2	1	50.0	1	2	100.0	0

TOTAL	46	13	41.9	18	15	48.4	16	31	67.4	15


	NPWT (n = 19)	Usual care (n = 21)	Total (n = 40)

Age (years)*	58·8(15·1)	56·9(13·9)	57·8(14·4)

Sex ratio (M : F)	11 : 8	11 : 10	22 : 18

BMI (kg/m2)*	29·2(5·6)	29·0(6·0)	29·1(5·7)

Diabetes	12	12	24

Peripheral arterial disease	7	7	14

Tobacco use

None	13	10	23

Ex‐smoker	1	6	7

Current (≤ 1 pack/day)	2	4	6

Current (> 1 pack/day)	3	1	4

Previous history of SWHSI

Yes	5	5	10

No	11	15	26

Unknown	3	1	4

Wound area (cm2)†	18·2 (0·2–122·5)	20·4 (2·3–93·2)	19·3 (0·2–122·5)

< 28	10	11	21

≥ 28	9	10	19

Wound duration (days)†	7 (0–27)	12 (1–142)	7 (0–142)

Wound infected

Yes	5	8	13

No	14	13	27

Wound location

Foot	11	13	24

Abdomen	3	3	6

Leg	3	1	4

Breast	1	1	2

Groin	0	2	2

Buttocks	0	1	1

Perianal area	1	0	1

Type of surgery‡

Elective	12	18	30

Emergency	6	3	9

Contamination level of surgery

Clean	6	2	8

Clean‐contaminated	9	12	21

Contaminated	4	7	11

Age (years)*

Sex ratio (M : F)

BMI (kg/m2)*

Diabetes

Peripheral arterial disease

Tobacco use

None

Ex‐smoker

Current (≤ 1 pack/day)

Current (> 1 pack/day)

Previous history of SWHSI

Yes

No

Unknown

Wound area (cm2)†

< 28

≥ 28

Wound duration (days)†

Wound infected

Yes

No

Wound location

Foot

Abdomen

Leg

Breast

Groin

Buttocks

Perianal area

Type of surgery‡

Elective

Emergency

Contamination level of surgery

Clean

Clean‐contaminated

Contaminated


SPACE	ESPACE

No.	Gene	Degree	No.	Gene	Degree

1	PRC1	26	1	AURKA	36

2	RRM2	17	2	NKX2-1	35

3	GPR116	16	3	RRM2	18


Model description

	Y	No. of variables	No. of observations	Degrees of freedom

	SMR	3	2306	2303

Model fit

	R2		Log likelihood	AIC

	0.2238		-235.357	476.713

Model estimation

	Variable	Coefficient	Std. Error	t-Statistic	P

	ρ	0.4962	0.0231	21.496	0.0000

	CONSTANT	0.3605	0.0304	11.859	0.0000

	AOD	0.5367	0.1522	3.527	0.0004

Diagnostic tests

	Tests	DF	Value	p

Heteroskedasticity	Breusch-Pagan	1	0.156	0.6933

Spatial dependence	Likelihood Ratio	1	434.813	0.2745

Model description

	Y	No. of variables

	SMR	3

Model fit

	R2

	0.2238

Model estimation

	Variable	Coefficient

	ρ	0.4962

	CONSTANT	0.3605

	AOD	0.5367

Diagnostic tests

	Tests

Heteroskedasticity	Breusch-Pagan

Spatial dependence	Likelihood Ratio

Model description

No. of observations	Degrees of freedom

2306	2303

Model fit

Log likelihood	AIC

-235.357	476.713

Model estimation

Std. Error	t-Statistic	P

0.0231	21.496	0.0000

0.0304	11.859	0.0000

0.1522	3.527	0.0004

DF	Value	p

1	0.156	0.6933

1	434.813	0.2745


Cancer types	Key message(s)	Ref.

Breast cancer	Dephosphorylation of FOXO3a induced by Aplysin suppresses tumor growth by inhibiting cell proliferation and promoting apoptosis in cancer cells.	[89]

Prostate cancer	Deregulation of FOXO3a promotes prostate cancer progression in TRAMP mice.	[90]

Acute myeloid leukemia	Dephosphorylation of FOXO3a induced by hypomethylating agents promote apoptosis by upregulation of BIM and PUMA expression.	[91]

Colon cancer	Activation of FOXO3a by aldose reductase induces human colon cancer cell apoptosis by upregulating both DR5 and DR4.	[92]

Lung cancer	Deregulation of FOXO3a promotes DNMT3B overexpression leading to tumor growth in lung cancer.	[93]

Glioma	A high expression of FOXO3a is associated with glioblastoma progression and FOXO3a level independently indicates poor prognosis in Glioma patients.	[94]

Thyroid cancer	Nuclear FOXO3a promotes cell cycle progression by transcriptional upregulation of cyclin A1 and accelerates proliferation of human ATC cells.	[95]

Lung adenocarcinoma	FOXO3a gene inactivation occurs frequently in carcinogen-induced lung adenocarcinoma.	[96]

Oral squamous cell carcinoma	Constitutively active form of FOXO3a induces significant G1-phase arrest and apoptosis in OSCC cells	[97]

Neck cancer	Tumor patients with low FOXO3a expression have a poor prognosis compared with patients with high FOXO3a.	[98]

Urothelial cancer	FOXO3a suppresses invasiveness of urothelial cancer through regulation of Twist1, YB-1 and E-cadherin.	[99]

Osteosarcoma	Activation of FOXO3a by ionizing radiation induces cell apoptosis in osteosarcoma.	[100]

Bladder cancer	Upregulation of FOXO3a by Nkx2.8 suppresses bladder cancer proliferation.

Gastric cancer	FOXO3a cooperates with RUNX3 to induce apoptosis by activating Bim in gastric cancer cells.	[60, 101]

Neuroblastoma	Inactivation of FOXO3a by AKT is essential for neuroblastoma cell survival.	[102]

Ovarian cancer	Inhibition of FOXO3a phosphorylation by BrMC upregulates Bim expression and leads to apoptosis in ovarian cancer cells.	[103]

Cancer types	Key message(s)

Breast cancer	Dephosphorylation of FOXO3a induced by Aplysin suppresses tumor growth by inhibiting cell proliferation and promoting apoptosis in cancer cells.

Prostate cancer	Deregulation of FOXO3a promotes prostate cancer progression in TRAMP mice.

Acute myeloid leukemia	Dephosphorylation of FOXO3a induced by hypomethylating agents promote apoptosis by upregulation of BIM and PUMA expression.

Colon cancer	Activation of FOXO3a by aldose reductase induces human colon cancer cell apoptosis by upregulating both DR5 and DR4.

Lung cancer	Deregulation of FOXO3a promotes DNMT3B overexpression leading to tumor growth in lung cancer.

Glioma	A high expression of FOXO3a is associated with glioblastoma progression and FOXO3a level independently indicates poor prognosis in Glioma patients.

Thyroid cancer	Nuclear FOXO3a promotes cell cycle progression by transcriptional upregulation of cyclin A1 and accelerates proliferation of human ATC cells.

Lung adenocarcinoma	FOXO3a gene inactivation occurs frequently in carcinogen-induced lung adenocarcinoma.

Oral squamous cell carcinoma	Constitutively active form of FOXO3a induces significant G1-phase arrest and apoptosis in OSCC cells

Neck cancer	Tumor patients with low FOXO3a expression have a poor prognosis compared with patients with high FOXO3a.

Urothelial cancer	FOXO3a suppresses invasiveness of urothelial cancer through regulation of Twist1, YB-1 and E-cadherin.

Osteosarcoma	Activation of FOXO3a by ionizing radiation induces cell apoptosis in osteosarcoma.

Bladder cancer	Upregulation of FOXO3a by Nkx2.8 suppresses bladder cancer proliferation.

Gastric cancer	FOXO3a cooperates with RUNX3 to induce apoptosis by activating Bim in gastric cancer cells.

Neuroblastoma	Inactivation of FOXO3a by AKT is essential for neuroblastoma cell survival.

Ovarian cancer	Inhibition of FOXO3a phosphorylation by BrMC upregulates Bim expression and leads to apoptosis in ovarian cancer cells.


Rate of failure in control group (%)	Rate of failure in the intervention group (%)

	10	15	25

	80% power	90% power	80% power	90% power	80% power	90% power

25	100	133

30	62	82	121	161

35	43	57	73	97	329	440


Variables	Renal cell carcinoma (n = 76)

Age (mean, years)	61.3 ± 13.5

Sex

Male	45

Female	31

Tumor type

Clear cell	59

Papillary	11

Chromophobe	4

Sarcomatoid carcinoma	2

Pathologic grade

Grade 1 and 2	57

Grade 3 and 4	19

Tumor stage

Stage 1 and 2	52

Stage 3 and 4	24


	2003	2004	2005	2006	2007	Total

Number of complicated induced abortions 	23	13	11	18	46	111

Number of admission into gynaecological ward	757	716	471	785	818	3547

Number of live births	1543	1479	1512	1756	2101	8391

Percentage of gynaecological admission 	3.0	1.8	2.3	2.3	5.6	3.1%

Ratio of complicated induced abortion per 1000 live births 	14.9	8.8	7.3	10.3	21.9	13.2/1000


Year	Journal	Title of the paper	First author; volume number; page numbers

2013	Public health action	The burden and outcomes of childhood tuberculosis in Cotonou, Benina	Ade S; vol 314; no 1; 15–19

2013	Public health action	MDR-TB treatment needs in patients previously treated for TB in Cotonou, Beninb	Ade S; vol 3; no 2; 160–165

2013	Transactions of the royal society of tropical medicine and hygiene	National profile and treatment outcomes of adult smear-negative pulmonary TB patients in Beninb	Ade S; 10.1093/trstmh/trt092

2014	PLoS One	National profile and treatment outcomes of patients with extrapulmonary tuberculosis in Benina	Ade S; vol 9; no 4; e95603

2015	Public health action	Low prevalence of diabetes mellitus in patients with tuberculosis in Cotonou, Beninb	Ade S; vol 5; no 2; 147–149

2016	BMC health services research	Follow-up and tracing of tuberculosis patients who fail to attend their scheduled appointments in Cotonou, Benin: a retrospective cohort studya	Ade S; vol 5; no 2; 7 pages; 10.1186/s12913-015-1219-z

2016	Tuberculosis research and treatment	Characteristics and treatment outcomes of retreatment tuberculosis patients in Beninb	Ade S; vol 2016, Article ID 1468631, 7 pages http://dx.doi.org/10.1155/2016/1468631

2016	Tuberculosis research and treatment	Tuberculosis case finding in Benin, 2000–2014 and beyond: a retrospective cohort and Time Series Studyb	Ade S; volume 2016, Article ID 3205843, 9 pages http://dx.doi.org/10.1155/2016/3205843

Year	Journal	Title of the paper	First author; volume number; page numbers

2013	Public health action	MDR-TB treatment needs in patients previously treated for TB in Cotonou, Beninb	Ade S; vol 3; no 2; 160–165

2013	Transactions of the royal society of tropical medicine and hygiene	National profile and treatment outcomes of adult smear-negative pulmonary TB patients in Beninb	Ade S; 10.1093/trstmh/trt092

2014	PLoS One	National profile and treatment outcomes of patients with extrapulmonary tuberculosis in Benina	Ade S; vol 9; no 4; e95603

2015	Public health action	Low prevalence of diabetes mellitus in patients with tuberculosis in Cotonou, Beninb	Ade S; vol 5; no 2; 147–149

2016	BMC health services research	Follow-up and tracing of tuberculosis patients who fail to attend their scheduled appointments in Cotonou, Benin: a retrospective cohort studya	Ade S; vol 5; no 2; 7 pages; 10.1186/s12913-015-1219-z

2016	Tuberculosis research and treatment	Characteristics and treatment outcomes of retreatment tuberculosis patients in Beninb	Ade S; vol 2016, Article ID 1468631, 7 pages http://dx.doi.org/10.1155/2016/1468631

2016	Tuberculosis research and treatment	Tuberculosis case finding in Benin, 2000–2014 and beyond: a retrospective cohort and Time Series Studyb	Ade S; volume 2016, Article ID 3205843, 9 pages http://dx.doi.org/10.1155/2016/3205843


Treatment [Reference]	Annual exacerbation rate	Comparator	Annual exacerbation rate	Reduction in exacerbations	Exacerbation endpoint	Patient population

Exacerbation entry criteria (No./year)	FEV1 % predicted

ICS

 FP [131]	0.93	Placebo	0.73	NS	Primary	NA	<90 % (post-BD)

 FP [13]	0.93	Placebo	1.13	18 %	Secondary (moderate or severe)	NA	<60 % (pre-BD)

 FP [65]	1.05	Placebo	1.30	19 %	Secondary (any)	≥1	25–70 % (pre-BD)

 FP [132]	0.99	Placebo	1.32	25 %	Secondary (any)	NA	<85 % (post-BD)

LABA/ICS

 SFC [133]	0.44	Salmeterol	0.48	NS	Primary (severe)	≥1 (last 14 days)	<70 % (pre-BD)

 SFC [134]	1.10	Salmeterol	1.59	30.4 %	Primary (moderate or severe)	≥1	<50 %

 SFC [13]	0.85	PlaceboSalmeterolFP	1.130.970.93	25 %12 %9 %	Secondary (moderate or severe)	NA	<60 % (pre-BD)

 SFC [65]	0.97	Placebo	1.30	25 %	Secondary (moderate)	≥1	25–70 % (pre-BD)

 SFC [135]	1.06	Salmeterol	1.53	30.5 %	Primary	≥1	<50 %

 SFC [61, 136]	1.28	Tiotropium	1.32	NS	Primary (moderate or severe)	NA	<50 % (post-BD)

 SFC [137]	0.92	Salmeterol	1.4	35 %	Primary (moderate or severe)	≥2	<50 % (post-BD)

 Bud/Form [80]	1.38	PlaceboFormeterolBudesonide	1.801.851.60	23.6 %NSNS	Primary (all)	≥1	<50 % (pre-BD)

 Bud/Form [81]	1.42	PlaceboFormoterolBudesonide	1.871.841.59	24 %23 %NS	Primary (severe)	≥1	<50 %

 Bud/Form [138]	0.70 (320/9 μg)0.79 (160/9 μg)	Formoterol	1.07	34.6 %25.9 %	Primary (moderate or severe)	≥1	≤50 % (pre-BD)

 Bud/Form [139]	NR	Formoterol	NR	36 %	Secondary (any)	≥1	≤50 % (pre-BD)

 FF/VI [79]	0.81	Vilanterol	1.11	30 %(Pooled data)	Primary (moderate or severe)	≥1	<70 % (post-BD)

 BDP/FOR [140]	0.80	Formoterol	1.12	28 %	Primary (moderate or severe)	≥1	<50 %

 BDP/FOR [141]	0.41	Bud/Form Formoterol	0.420.43	NS	Primary	≥1	30–50 % (post-BD)

Triple therapy

 Tiotropium + salmeterol + FP [64]	1.37	Tiotropium	1.61	NS	Secondary (any)	≥1	<65 % (post-BD)

Treatment [Reference]	Annual exacerbation rate	Comparator	Annual exacerbation rate	Reduction in exacerbations	Exacerbation endpoint	Exacerbation entry criteria (No./year)	FEV1 % predicted

ICS

FP [131]	0.93	Placebo	0.73	NS	Primary	NA	<90 % (post-BD)

FP [13]	0.93	Placebo	1.13	18 %	Secondary (moderate or severe)	NA	<60 % (pre-BD)

FP [65]	1.05	Placebo	1.30	19 %	Secondary (any)	≥1	25–70 % (pre-BD)

FP [132]	0.99	Placebo	1.32	25 %	Secondary (any)	NA	<85 % (post-BD)

LABA/ICS

SFC [133]	0.44	Salmeterol	0.48	NS	Primary (severe)	≥1 (last 14 days)	<70 % (pre-BD)

SFC [134]	1.10	Salmeterol	1.59	30.4 %	Primary (moderate or severe)	≥1	<50 %

SFC [13]	0.85	PlaceboSalmeterolFP	1.130.970.93	25 %12 %9 %	Secondary (moderate or severe)	NA	<60 % (pre-BD)

SFC [65]	0.97	Placebo	1.30	25 %	Secondary (moderate)	≥1	25–70 % (pre-BD)

SFC [135]	1.06	Salmeterol	1.53	30.5 %	Primary	≥1	<50 %

SFC [61, 136]	1.28	Tiotropium	1.32	NS	Primary (moderate or severe)	NA	<50 % (post-BD)

SFC [137]	0.92	Salmeterol	1.4	35 %	Primary (moderate or severe)	≥2	<50 % (post-BD)

Bud/Form [80]	1.38	PlaceboFormeterolBudesonide	1.801.851.60	23.6 %NSNS	Primary (all)	≥1	<50 % (pre-BD)

Bud/Form [81]	1.42	PlaceboFormoterolBudesonide	1.871.841.59	24 %23 %NS	Primary (severe)	≥1	<50 %

Bud/Form [138]	0.70 (320/9 μg)0.79 (160/9 μg)	Formoterol	1.07	34.6 %25.9 %	Primary (moderate or severe)	≥1	≤50 % (pre-BD)

Bud/Form [139]	NR	Formoterol	NR	36 %	Secondary (any)	≥1	≤50 % (pre-BD)

FF/VI [79]	0.81	Vilanterol	1.11	30 %(Pooled data)	Primary (moderate or severe)	≥1	<70 % (post-BD)

BDP/FOR [140]	0.80	Formoterol	1.12	28 %	Primary (moderate or severe)	≥1	<50 %

BDP/FOR [141]	0.41	Bud/Form Formoterol	0.420.43	NS	Primary	≥1	30–50 % (post-BD)

Triple therapy

Tiotropium + salmeterol + FP [64]	1.37	Tiotropium	1.61	NS	Secondary (any)	≥1	<65 % (post-BD)


Item		Group 1: feedback report (n = 9)	Group 2: feedback report with appendix (n = 11)	P-value

Mean (CI)	Mean (CI)

Scale 1–10	Scale 1–10

1a	I think that the patient safety culture feedback report is....

	 Understandable	6.1 (4.8–7.5)	7.3 (6.0–8.6)	0.04*

	 Interesting	7.6 (7.0–8.1)	7.6 (6.7–8.6)	0.53

	 Useful	6.8 (3.0–7.5)	7.2 (5.8–8.6)	0.10

	 Relevant	7.3 (6.8–7.9)	7.8 (7.3–8.3)	0.20

	 Well-ordered	6.7 (5.9–7.4)	7.5 (6.4–8.5)	0.12

	 Complete	6.9 (6.2–7.6)	7.4 (6.6–8.2)	0.45

	 Attractive (lay-out)	6.8 (6.3–7.3)	7.6 (7.0–8.3)	0.04*

		N (%)	N (%)

2b	Do you miss any results in this report?	5 (56 %)	7 (64 %)

 Yes			1.000

3b	Which statement reflects the patient safety culture report best:	6 (67 %)	5 (46 %)	0.49

 we now see suggestions to improve patient safety culture	1 (11 %)	4 (36 %)

 we now have insight, but we do not know how to improve	2 (22 %)	1 (9 %)

 this report has brought us little new information different statements	-	1 (9 %)

Item		Group 1: feedback report (n = 9)	Group 2: feedback report with appendix (n = 11)	P-value

Mean (CI)	Mean (CI)

Scale 1–10	Scale 1–10

1a	I think that the patient safety culture feedback report is....

	Understandable	6.1 (4.8–7.5)	7.3 (6.0–8.6)	0.04*

	Interesting	7.6 (7.0–8.1)	7.6 (6.7–8.6)	0.53

	Useful	6.8 (3.0–7.5)	7.2 (5.8–8.6)	0.10

	Relevant	7.3 (6.8–7.9)	7.8 (7.3–8.3)	0.20

	Well-ordered	6.7 (5.9–7.4)	7.5 (6.4–8.5)	0.12

	Complete	6.9 (6.2–7.6)	7.4 (6.6–8.2)	0.45

	Attractive (lay-out)	6.8 (6.3–7.3)	7.6 (7.0–8.3)	0.04*

		N (%)	N (%)

2b	Do you miss any results in this report?	5 (56 %)	7 (64 %)

Yes			1.000

	Which 	6 (6	5	0.

3b	statement reflects the patient safety culture report best:	7 %)	 (46 %)	49

we now see suggestions to improve patient safety culture	1 (11 %)	4 (36 %)

we now have insight, but we do not know how to improve	2 (22 %)	1 (9 %)

this report has brought us little new information different statements	-	1 (9 %)


		Aguie

Total population

Number of households/respondents	735

Number of children under 5 yo	1550

Number (%) of households with

	1 to 2 children < 5 yo	535 (72.8)

	3 to 5 children < 5 yo	192 (26.1)

	more than 5 children < 5 yo	8 (1.1)

Number (%) of respondents with

	0 years of education	680 (92.5)

	1 to 6 years of education	35 (4.8)

	more than 6 years of education	20 (2.7)

Selected population

Selected children	735

Sex ratio M/F	0.96

Age

	median (month) (IQR)	23 (12-35)

	< 1 year (%)	214 (29.1)

	1 - 2 years (%)	202 (27.5)

	2 - 3 years (%)	163 (22.2)

	3 - 4 years (%)	106 (14.4)

	4 - 5 years (%)	49 (6.7)


Land-cover type	Proportion of area of suitable habitat (%) 1	Mean habitat suitability (%)

Madrean Encinal	6.3	47.1

Madrean Pinyon-Juniper Woodland	12.6	40.7

Mogollon Chaparral	2.5	38.8

Chihuahuan Mixed Salt Desert Scrub	2.5	34.7

Madrean Lower Montane Pine-Oak Forest and Woodland	1.4	34.6

Apacherian-Chihuahuan Mesquite Upland Scrub	10.6	22.6

Apacherian-Chihuahuan Semi-Desert Grassland and Steppe	28.2	18.9

Chihuahuan Creosote, Mixed Desert and Thorn Scrub	10.4	16.7

Southern Rocky Mountain Ponderosa Pine Woodland	8.5	14.6

Colorado Plateau Pinyon-Juniper Woodland	5.1	13.9

Chihuahuan Stabilized Coppice Dune and Sand Flat Scrub	1.2	8.3

Sonoran Paloverde-Mixed Cacti Desert Scrub	2.8	5.9

Land-cover type	Proportion of area of suitable habitat (%) 1

Madrean Encinal	6.3

Madrean Pinyon-Juniper Woodland	12.6

Mogollon Chaparral	2.5

Chihuahuan Mixed Salt Desert Scrub	2.5

Madrean Lower Montane Pine-Oak Forest and Woodland	1.4

Apacherian-Chihuahuan Mesquite Upland Scrub	10.6

Apacherian-Chihuahuan Semi-Desert Grassland and Steppe	28.2

Chihuahuan Creosote, Mixed Desert and Thorn Scrub	10.4

Southern Rocky Mountain Ponderosa Pine Woodland	8.5

Colorado Plateau Pinyon-Juniper Woodland	5.1

Chihuahuan Stabilized Coppice Dune and Sand Flat Scrub	1.2

Sonoran Paloverde-Mixed Cacti Desert Scrub	2.8


Request	Time for the injury prevention request to be responded (ms)

Average	8702.68164

Median	11257


Rank	Topic	Mean	Median

1	Newborn circumcision	1.36	1

2	Reduce paraphimosis	1.36	0

3	Vasectomy	1.18	0

4	Drain hydrocoele	1.00	0

5	Bladder catheterization	0.91	1

6	Intracavernosal injections	0.82	0

7	Adult circumcision	0	0

8	Prostate biopsy	0	0

Rank	Topic	Mean	Median

8	Prostate biopsy	0	0


 	Baseline	Routine clinic visitsa

Fasting plasma glucose	√	√

Fasting insulin	√	√

Glycated haemoglobin A1c	√	√

Serum triglycerides	√	√

Cholesterol	√	√

High-density lipoprotein	√	√

Low-density lipoprotein	√	√

Apolipoprotein B/apolipoprotein A1	√	√

Serum sodium	√	√

Serum potassium	√	√

Serum renin	√	√

Serum osteocalcin	√	√

Serum procollagen I N-terminal propeptide	√	√

Fasting plasma glucose

Fasting insulin

Glycated haemoglobin A1c

Serum triglycerides

Cholesterol

High-density lipoprotein

Low-density lipoprotein

Apolipoprotein B/apolipoprotein A1

Serum sodium

Serum potassium

Serum renin

Serum osteocalcin

Serum procollagen I N-terminal propeptide

Baseline	Routine clinic visitsa

√	√

√	√

√	√

√	√

√	√

√	√

√	√

√	√

√	√

√	√

√	√

√	√

√	√


Al(III) (μM)

0

30

Nano-Al13 (μM)

0

30


Males (%)

Age (years) (mean ± SD)

Use ASD (%)

Previous ankle injury (%)

Coach enforcement of ASD (%)


 	Group <70 yrs (n)	Group ≥70 yrs (n)

Pulmonary embolism	2	4

Hypertension	6	8

Atrial fibrillation	5	5

Pneumonia	1	2

Leucopenia	4	7

Prolonged ileus	8	10

Urinary tract infections	4	6

Drainage of intra-abdominal collection	2	4

Reoperation	5	3

 Pancreatic fistula	1	1

 Hemorrhage	3	1

 Peritonitis	1	1


Variable	0 min	30 min	60 min	90 min

Heart rate (bpm)Meltdown®	59 ± 3	63 ± 2	62 ± 2	63 ± 2

Heart rate (bpm)Placebo	59 ± 3	60 ± 3	62 ± 3	60 ± 3

Systolic Blood Pressure (mmHg)Meltdown® *	117 ± 2	122 ± 3	123 ± 2	122 ± 3

Systolic Blood Pressure (mmHg)Placebo	118 ± 2	118 ± 2	117 ± 1	116 ± 1

Diastolic Blood Pressure (mmHg)Meltdown®	72 ± 1	71 ± 2	72 ± 2	70 ± 2

Diastolic Blood Pressure (mmHg)Placebo	72 ± 1	72 ± 2	71 ± 1	71 ± 1

Variable	0 min	30 min	60 min	90 min

Heart rate (bpm)Meltdown®	59 ± 3	63 ± 2	62 ± 2	63 ± 2

Heart rate (bpm)Placebo	59 ± 3	60 ± 3	62 ± 3	60 ± 3

Systolic Blood Pressure (mmHg)Meltdown® *	117 ± 2	122 ± 3	123 ± 2	122 ± 3

Systolic Blood Pressure (mmHg)Placebo	118 ± 2	118 ± 2	117 ± 1	116 ± 1

Dias		71 ± 2	72 ±	70 ±

tolic Blood Pressure (mmHg)Meltdown®	72 ± 1		 2	 2

Diastolic Blood Pressure (mmHg)Placebo	72 ± 1	72 ± 2	71 ± 1	71 ± 1


Missed appointment	Missed doses	Total

No	Yes

No	694 (94.3)	42 (5.7)	736

Yes	17 (70.8)	7 (29.2)	24


Tag sequence	Tags	TPMa	UniGene ID	Gene	Cluster name	Biological Functionb

TACCTGCAGA	515	16930	Hs.416073	S100A8	S100 calgranulin A	Regulation of cell cycle progression and differentiation.

TAGGTTGTCT	356	11703	Hs.374596	TPT1	Tumor protein, translationally-controlled 1	Unknown

TTTCCTGCTC	276	9073	Hs.139322	SPRR3	Small proline-rich protein 3	Cross-linked envelope protein of keratinocytes

GAGGGAGTTT	201	6607	Hs.523463	RPL27A	Ribosomal protein L27a	Component of the ribosomal 60S subunit

GTGACCACGG	188	6180	Hs.436980	GRIN2C	Glutamate receptor, N-methyl D-aspartate 2C	Ionotropic glutamate receptor

GTGGCCACGG	184	6049	Hs.112405	S100A9	S100 calcium binding protein A9 (calgranulin B)	Regulation of cell cycle progression and differentiation.

GGGCTGGGGT	173	5687	Hs.425125; Hs.90436	RPL29; SPAG7	Ribosomal protein L29; Sperm associated antigen 7	Component of the ribosomal 60S subunit.

GCATAATAGG	168	5523	Hs.381123	RPL21	Ribosomal protein L21	Component of the ribosomal 60S subunit.

TCAGATCTTT	161	5292	Hs.446628	RPS4X	Ribosomal protein S4, X-linked	Component of the ribosomal 40S subunit.

GTTGTGGTTA	155	5095	Hs.99785		FLJ21245	Unknown

GGATTTGGCC	151	4964	Hs.437594	RPLP2	Ribosomal protein, large P2	Component of the ribosomal 60S subunit.

TTGGGGTTTC	143	4701	Hs.448738	FTH1	Ferritin, heavy polypeptide 1	Important for iron homeostasis, stores iron in a soluble, nontoxic, readily available form.

TTGGTCCTCT	138	4536	Hs.381172	RPL41	Rribosomal protein L41	Component of the ribosomal 60S subunit.

TGCACGTTTT	130	4273	Hs.265174	RPL32	Ribosomal protein L32	Component of the ribosomal 60S subunit.

ACAAAGCATT	128	4208	Hs.369982	IGFBP5	Insulin-like growth factor binding protein 5	IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGF on cell culture.

AGGGCTTCCA	122	4010	Hs.401929	RPL10	Ribosomal protein L10	Component of the ribosomal 60S subunit.

CCACTGCACT	114	3747	Hs.107003	CCNB1IP1	Cyclin B1 interacting protein 1	Functions in progression of the cell cycle through G(2)/M.

GGCAAGCCCC	107	3517	Hs.148340	RPL10A	ribosomal protein L10a	Component of the ribosomal 60S subunit.

CTGGGTTAAT	105	3451	Hs.334534	GNS	Glucosamine (N-acetyl)-6-sulfatase	Lysosomal enzyme found in all cells. It is involved in the catabolism of heparin, heparan sulphate, and keratan sulphate.

TGCACTTCAA	103	3386	Hs.62886	SPARCL1	SPARC-like 1 (mast9, hevin)	Calcium ion binding

Tag sequence	Tags	TPMa	UniGene ID	Gene	Cluster name	Biological Functionb

ACAAAGCATT	128	4208	Hs.369982	IGFBP5	Insulin-like growth factor binding protein 5	IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGF on cell culture.

AGGGCTTCCA	122	4010	Hs.401929	RPL10	Ribosomal protein L10	Component of the ribosomal 60S subunit.

CCACTGCACT	114	3747	Hs.107003	CCNB1IP1	Cyclin B1 interacting protein 1	Functions in progression of the cell cycle through G(2)/M.

GGCAAGCCCC	107	3517	Hs.148340	RPL10A	ribosomal protein L10a	Component of the ribosomal 60S subunit.

CTGGGTTAAT	105	3451	Hs.334534	GNS	Glucosamine (N-acetyl)-6-sulfatase	Lysosomal enzyme found in all cells. It is involved in the catabolism of heparin, heparan sulphate, and keratan sulphate.

TGCACTTCAA	103	3386	Hs.62886	SPARCL1	SPARC-like 1 (mast9, hevin)	Calcium ion binding


	Presence/absence of IgG in oral fluid at six months	Presence/absence of IgG in oral fluid before measles vaccination at nine months

Variable	OR	95% CI	OR	95% CI

Gender (F, M)	1.1	0.74–1.61	1.1	0.78–1.55

Breast feeding (Yes, No)	1.02	1–1.04	0.88	0.39–1.95

Measles history (Yes, No)	1.39	0.17–11.43	0.78	0.14–4.28

Type of birth (Normal, Caesarean)	0.94	0.81–1.83	1.18	0.58–2.39

Low-birth-weight (Yes, No)	1.03	0.25–4.21	0.78	0.44–1.36

Prematurity (Yes, No)	1.02	0.7–1.48	0.57	0.31–1.05

Weight for height cat (≥ -2, <-2)	-	-	0.78	0.32–1.87

Weight for age cat (≥ -2, <-2)	0.59	0.1–3.58	2.16	0.75–6.19

Height for age cat (≥ -2, <-2)	1.26	0.46–3.46	0.79	0.55–1.13

Mother's IgG (Pos, Neg*)	1.96	0.62–6.17	1.57	0.86–2.87

Mother's age ≤ 28 y, ≥ 29 y	0.81	0.29–2.32	1.15	0.61–2.19


Variable	Frequency	(%)

Sex

Male	241	54.7 %

Female	199	45.3 %

Age

15-24	89	20.2 %

25-34	112	25.5 %

35-44	85	19.3 %

45-54	65	14.8 %

55-64	49	11.1 %

>64	40	9.1 %

Ethnicity

Oromo	306	69.5 %

Amhara	50	11.5 %

Dawro	43	9.8 %

Othersa	41	9.3 %

Religion

Muslim	332	75.5 %

Orthodox	78	17.7 %

Protestant	30	6.8 %

Educational status

Illiterate	221	50.2 %

Read and write	73	16.6 %

Elementary	113	25.7 %

Secondary education	33	7.5 %

& above

Occupations

Farmers	260	59.1 %

House wives	83	18.9 %

Students	74	16.8 %

Othersb	23	5.2 %


Gestation	Study cohort	Previous study cohort

	N*	%	N**	%

14–17 weeks	147	4	0	0

18–22 weeks	578	16	0	0


gliomas	Number of cases (tissue cores)

Glioblastoma (GBM, WHO Grade IV)	128 (256)

Anaplastic astrocytoma (AA, WHO Grade III)	27 (54)

Diffuse astrocytoma (LGA, WHO Grade II)	33 (66)

Anaplastic oligodendroglioma (AO, WHO Grade III)	16 (32)

Oligodendroglioma (ODG, WHO Grade II)	26 (52)

Anaplastic mixed oligoastrocytoma (AMOA, WHO Grade III)	30 (60)

Oligoastrocytoma (MOA, WHO Grade II)	32 (64)

non neoplastic brain tissue(NB)	13 (26)

gliomas	Number of cases (tissue cores)

Diffuse astrocytoma (LGA, WHO Grade II)	33 (66)

Anaplastic oligodendroglioma (AO, WHO Grade III)	16 (32)

Oligodendroglioma (ODG, WHO Grade II)	26 (52)

Anaplastic mixed oligoastrocytoma (AMOA, WHO Grade III)	30 (60)

Oligoastrocytoma (MOA, WHO Grade II)	32 (64)

non neoplastic brain tissue(NB)	13 (26)


		1	2	3	4	5

1	PTSD – Re-experiencing

2	PTSD – Avoidance	0.48**

3	PTSD – Arousal	0.48**	0.49**

4	DSO – Affect Dysregulation	0.37**	0.40**	0.48**

5	DSO – Disturbances in Self-Concept	0.36**	0.45**	0.46**	0.50**

6	DSO – Difficulties in Interpersonal Relationships	0.27**	0.24**	0.30**	0.47**	0.21*


SOFIT activity category

Lesson Time

Minutesa

Sitting

Minutes per lesson

Percentage of time per lesson

Standing

Minutes per lesson

Percentage of time per lesson

Walking

Minutes per lesson

Percentage of time per lesson

Very Active

Minutes per lesson

Percentage of time per lesson

MVPA (Walking plus Very Active)

Minutes per lesson

Percentage of time per lesson


Complication	Number of complications (%)

Bleeding	10 (3.8)

Aspiration	2 (0.7)

Fistula	2 (0.7)

Wound healing disorders	1 (0.7)

Nerve lesions	3 (1.1)

Other complications	2 (0.7)

Complication	Number of complications (%)

Wound healing disorders	1 (0.7)

Nerve lesions	3 (1.1)

Other complications	2 (0.7)


Subjectsb	Vbeta	CDR3	BJ	Ratioc

J24 (CD4+)	BV24	AAMYLCATS	SDRVSPL	HFGNGTRLTVTED	1.6	22/25

J23	BV20	SGFYLCAWS	VQVGWGETQ	YFGPGTRLLVLED	2.5	12/21

J24 (CD4+)	BV20	SGFYLCAWS	TGTGHSPL	HFGNGTRLTVTED	1.6	21/25

J28 (CD8+)	BV20	SGFYLCAWS	TGTGHSPL	HFGNGTRLTVTED	1.6	20/24

J38	BV20	SGFYLCAWS	TGTGHSPL	HFGNGTRLTVTED	1.6	22/25

J32 (CD4+)	BV14	SLYFCASS	PGTTQETQ	YFGSGTRLLVLED	2.5	18/23

J25	BV14	SLYFCASS	PGTTQETQ	YFGPGTRLTVLED	2.5	15/23

J28 (CD8+)	BV14	SLYFCASS	RHTGGTEA	FFGQGTRLTVVED	1.1	19/30

J29	BV13.2	TSVYFCASS	YDENEQ	FFGPGTRLTVLED	2.1	16/22

J31 (CD4+)	BV13.2	TSVYFCASK	TKPVGEQ	FFGPGTRLTVLED	2.1	15/23

J42	BV13.1	TSVYFCASS	YSAGGPNEQ	FFGPGTRLTVLED	2.1	18/25

J34 (CD4+)	BV12	TSVYFCAIR	KQGDSYEQ	YFGPGTRLTVTED	2.7	17/23

J35	BV12	TSVYFCASR	VRLITNYGY	TFGSGTRLTVVED	1.2	24/24

J39 (CD4+)	BV12	TSVYFCATA	GGAPGQPQ	HFGDGTRLSILED	1.5	16/24

J23	BJ5.1	SALYLCASS	LDYSGNTI	YFGEGSWLTVVED	1.3	22/27

J25 (CD8+)	BJ5.1	SALYLCASS	LDYSGNTI	YFGEGSWLTVVED	1.3	22/27

J30	BJ5.1	SALYLCASS	LDYSGNTI	YFGEGSWLTVVED	1.3	22/25

J24	BV3	SMYLCASG	PNYYEQ	YFGPGTRLTVTED	2.7	23/25

Subjectsb	Vbeta	CDR3	BJ	Ratioc

J23	BV20	SGFYLCAWS	VQVGWGETQ	YFGPGTRLLVLED	2.5	12/21

J24 (CD4+)	BV20	SGFYLCAWS	TGTGHSPL	HFGNGTRLTVTED	1.6	21/25

J28 (CD8+)	BV20	SGFYLCAWS	TGTGHSPL	HFGNGTRLTVTED	1.6	20/24

J38	BV20	SGFYLCAWS	TGTGHSPL	HFGNGTRLTVTED	1.6	22/25

J32 (CD4+)	BV14	SLYFCASS	PGTTQETQ	YFGSGTRLLVLED	2.5	18/23

J25	BV14	SLYFCASS	PGTTQETQ	YFGPGTRLTVLED	2.5	15/23

J28 (CD8+)	BV14	SLYFCASS	RHTGGTEA	FFGQGTRLTVVED	1.1	19/30

J29	BV13.2	TSVYFCASS	YDENEQ	FFGPGTRLTVLED	2.1	16/22

J31 (CD4+)	BV13.2	TSVYFCASK	TKPVGEQ	FFGPGTRLTVLED	2.1	15/23

J42	BV13.1	TSVYFCASS	YSAGGPNEQ	FFGPGTRLTVLED	2.1	18/25

J34 (CD4+)	BV12	TSVYFCAIR	KQGDSYEQ	YFGPGTRLTVTED	2.7	17/23

J35	BV12	TSVYFCASR	VRLITNYGY	TFGSGTRLTVVED	1.2	24/24

J39 (CD4+)	BV12	TSVYFCATA	GGAPGQPQ	HFGDGTRLSILED	1.5	16/24

J23	BJ5.1	SALYLCASS	LDYSGNTI	YFGEGSWLTVVED	1.3	22/27

J25 (CD8+)	BJ5.1	SALYLCASS	LDYSGNTI	YFGEGSWLTVVED	1.3	22/27

J30	BJ5.1	SALYLCASS	LDYSGNTI	YFGEGSWLTVVED	1.3	22/25

J24	BV3	SMYLCASG	PNYYEQ	YFGPGTRLTVTED	2.7	23/25


Activity category	Observed activity	Definition

(1) Nil physical activity	Lying in bed sleeping, talking, reading, eating, watching TV, or doing nothing in particular	Sedentary

(2) Minimal physical activity	Sitting supported out of bed while talking, reading, eating, or doing nothing	Sedentary

(3) Light physical activity	Rolling to sit up, sitting unsupported, or transferring with feet on floor	Physically active

(4) Moderate physical activity	Standing, walking, or climbing stairs	Physically active

Activity category	Observed activity

(1) Nil physical activity	Lying in bed sleeping, talking, reading, eating, watching TV, or doing nothing in particular

(2) Minimal physical activity	Sitting supported out of bed while talking, reading, eating, or doing nothing

(3) Light physical activity	Rolling to sit up, sitting unsupported, or transferring with feet on floor

(4) Moderate physical activity	Standing, walking, or climbing stairs

Definition

Sedentary

Sedentary

Physically active

Physically active


AH	Positiona	Lengthb	Hydr. momc	Fract of residuesd	Lipid-binding properties	Ref

Hdr	LH	Ch

Hel 13-5	n.a.e	18	0.69	0.72	0.06	0.28	Tubulates liposomes	73

GMAP210	1–38 (1979)	38	0.48	0.37	0.05	0.05	Golgi vesicles/abundant packing defects	14, 25

Nup133	247–267 (1156)	21	0.44	0.38	0.05	0.10	Nuclear pore membrane	67

CIDEA	163–180 (219)	18	0.53	0.5	0.11	0.17	LDsf	28

CCTα	236–294 (368)	59	0.48*	0.32	0.10	0.49	Nuclear envelope/ER and LDs/liposomes	6, 16,64

Apolipoprotein-AI	74–267 (267)	186 (7 P)g	0.39*	0.40	0.065	0.35	Lipoprotein particles	48

α-Synuclein	1–89 (144)	89	0.30*	0.47	0.02	0.24	Synaptic vesicles/neg. charged small liposomes	44

Plin3	114–204 (434)	90	0.35*	0.37	0.01	0.23	LDs and cytosol	11

Plin4	70–1037 (1357)	968	(0.257)*	0.35	0.002	0.15	This study

AH	Positiona	Lengthb	Hydr. momc	Fract of residuesd	Lipid-binding properties	Ref

Hdr	LH	Ch

Hel 13-5	n.a.e	18	0.69	0.72	0.06	0.28	Tubulates liposomes	73

GMAP210	1–38 (1979)	38	0.48	0.37	0.05	0.05	Golgi vesicles/abundant packing defects	14, 25

Nup133	247–267 (1156)	21	0.44	0.38	0.05	0.10	Nuclear pore membrane	67

CIDEA	163–180 (219)	18	0.53	0.5	0.11	0.17	LDsf	28

CCTα	236–294 (368)	59	0.48*	0.32	0.10	0.49	Nuclear envelope/ER and LDs/liposomes	6, 16,64

Apolipoprote	74–	186 (7 P)	0.3			0.35	Lip	4


Links between mutant GBA and PD	References

Subset of GD patients develop parkinsonism	Bembi et al. (2003), Neudorfer et al. (1996), Tayebi et al. (2001)

Genetic multi-centre study reporting statistically significant association between GBA mutations and PD	Sidransky et al. (2009)

Lewy bodies similar in PD brains with and without GBA mutations	Neumann et al. (2009), Parkkinen et al. (2011)

Accumulation and impaired turnover of α-synuclein in animal and cell models of GCase deficiency	Cullen et al. (2011), Fishbein et al. (2014), Manning-Boğ et al. (2009), Mazzulli et al. (2011), Osellame et al. (2013), Sardi et al. (2011), Schöndorf et al. (2014)

GCase activity decreased in sporadic PD	Gegg et al. (2012), Murphy et al. (2014)

α-synuclein affects GCase function	Gegg et al. (2012), Mazzulli et al. (2011), Sardi et al. (2013), Yap et al. (2011)

Links between mutant GBA and PD	References

Subset of GD patients develop parkinsonism	Bembi et al. (2003), Neudorfer et al. (1996), Tayebi et al. (2001)

Genetic multi-centre study reporting statistically significant association between GBA mutations and PD	Sidransky et al. (2009)

Lewy bodies similar in PD brains with and without GBA mutations	Neumann et al. (2009), Parkkinen et al. (2011)

Accumulation and impaired turnover of α-synuclein in animal and cell models of GCase deficiency	Cullen et al. (2011), Fishbein et al. (2014), Manning-Boğ et al. (2009), Mazzulli et al. (2011), Osellame et al. (2013), Sardi et al. (2011), Schöndorf et al. (2014)

GCase	Gegg et al. (2012), Murphy e

Links between mutant GBA and PD	References

 activity decreased in sporadic PD	t al. (2014)

α-synuclein affects GCase function	Gegg et al. (2012), Mazzulli et al. (2011), Sardi et al. (2013), Yap et al. (2011)


Type of atresia	Location	Survival

	Jejunal(n = 11)	Ileal(n = 17)	Survivors(n = 20)	Non-survivors(n = 8)

I	1	1	2	0

II	1	1	0	2

IIIa	2	12	14	0

IIIb	4	1	2	3

IV	3	2	2	3

Total	11	17	20	8

Type of atresia	Location	Survival

	Jejunal(n = 11)	Ileal(n = 17)	Survivors(n = 20)	Non-survivors(n = 8)

		1		0


Locality/region	N	Tick-infested dogs	Tick-free dogs	Odds ratio (95% CI)	P

		positive	negative	positive	negative

Putignano (C)	80	6	24	4	46	2.9 (0.7-11.2)	0.1640

Basilicata (D)	50	5	13	1	31	11.9 (1.3-112.3)	0.0184

Sicilia (E)	113	13	28	2	70	16.2 (3.4-76.7)	< 0.0001

Madrigal de la Vera (F)	51	9	32	2	8	1.1 (0.2-6.3)	1.000

Locality/region	N	Tick-infested dogs	Tick-free dogs	Odds ratio (95% CI)	P

		positive	negative	positive	negative

Xanthi (G)	23	1	8	0	14	5.1 (0.2-14.4)	0.3913


Mediterranean Diet	Paleo Diet

Lipids	Moderate Fat 40% of daily calories	Moderate-Low Fat 35% of daily calories

Proteins	Reduce processed and red meat. Increased plant-based protein, fish and poultry	Reduce processed and red meat. Increased plant-based protein, and meat from marine and game animals

Carbohydrates	Low Carbohydrate ≤40% of daily calories Fruits, vegetables, sugar, and grains	Moderate Carbohydrates ≤45–65% of daily calories Fruits and vegetables Decreased grains

Mediterranean Diet

Lipids

Proteins

Carbohydrates

Paleo Diet

Moderate Fat 40% of daily calories	Moderate-Low Fat 35% of daily calories

Reduce processed and red meat. Increased plant-based protein, fish and poultry	Reduce processed and red meat. Increased plant-based protein, and meat from marine and game animals

Low Carbohydrate ≤40% of daily calories Fruits, vegetables, sugar, and grains	Moderate Carbohydrates ≤45–65% of daily calories Fruits and vegetables Decreased grains


BSS algorithm	Amari indices

Experiment 1:static uncoupled oscillators	Experiment 2: static coupled sources	Experiment 3: dynamic coupled oscillators

AMICA	0.31	0.37	0.25

Extended Infomax	0.31	0.38	0.25

FastICA	0.32	0.30	0.26

PWC-ICA (1)	0.35	0.29	0.28

PWC-ICA (2)	0.34	0.41	0.26

PWC-ICA (4)	0.35	0.41	0.24

PWC-ICA (8)	0.30	0.41	 0.23 (p < 2.3E − 3)

PWC-ICA (1) Haar	0.30	0.32	0.25

PWC-ICA (2) Haar	 0.21 (p < 1.5E − 11)	0.35	 0.23 (p < 4.5E − 4)

PWC-ICA (4) Haar	 0.21 (p < 1.5E − 10)	0.40	 0.23 (p < 4.4E − 2)

PWC-ICA (8) Haar	 0.27 (p < 1.5E − 5)	0.38	0.24

Hilbert complex	 0.28 (p < 1.5E − 4)	0.38	 0.23 (p < 6.7E − 3)

Average baseline	0.36	0.42	0.36

BSS algorithm	Amari indices

Experiment 1:static uncoupled oscillators	Experiment 2: static coupled sources	Experiment 3: dynamic coupled oscillators

AMICA	0.31	0.37	0.25

Extended Infomax	0.31	0.38	0.25

FastICA	0.32	0.30	0.26

PWC-ICA (1)	0.35	0.29	0.28

PWC-ICA (2)	0.34	0.41	0.26

PWC-ICA (4)	0.35	0.41	0.24

PWC-ICA (8)	0.30	0.41	0.23 (p < 2.3E − 3)

PWC-ICA (1) Haar	0.30	0.32	0.25

PWC-ICA (2) Haar	0.21 (p < 1.5E − 11)	0.35	0.23 (p < 4.5E − 4)

PWC-ICA (4) Haar	0.21 (p < 1.5E − 10)	0.40	0.23 (p < 4.4E − 2)

PWC-ICA (8) Haar	0.27 (p < 1.5E − 5)	0.38	0.24

Hilbert complex	0.28 (p < 1.5E − 4)	0.38	0.23 (p < 6.7E − 3)

Aver	0	0.42	0


RGT2 mutant designation	Causative constitutive mutation2	Location in Rgt2	Other (likely irrelevant) mutations2

87	F113L	TM1

93	F113L	TM1

58	F113L	TM1	H517R

71	F113L	TM1	T130A, L161S

<underline>82</underline>	D116V	TM1	F562L

68	D116V	TM1	D619G

57	D116G	TM1	I398V, F527L, S754G

100	D116N	TM1	A226T, Y330C

111	D116G, L552S	TM1, ICH5	I111M, V324I, K570R

83	Q222P	TM4

112	Q222R	TM4

RGT2-11	R231K	TM5

98	R231G	TM5	D698G

50	R231G	TM5	M58R

103	G232S	TM5	V537A

<underline>59</underline>	G232S	TM5	F465Y, S733L

86	S236P	TM5	F465Y, G471S

<underline>81</underline>	S236P	TM5	K488R

<underline>493</underline>	S253P, S443P	TM5, TM9

47	D415N	TM8

60	W474R	TM10

95	V475M	TM10

<underline>52</underline>	L552S	ICH5	N723I

85	L552S	ICH5	V404G

1084	V473G?		V473G, D611G, I626V

924	?		G103S, F111L

Location in Rgt2	Other (likely irrelevant) mutations2

TM1

TM1

TM1	H517R

TM1	T130A, L161S

TM1	F562L

TM1	D619G

TM1	I398V, F527L, S754G

TM1	A226T, Y330C

TM1, ICH5	I111M, V324I, K570R

TM4

TM4

TM5

TM5	D698G

TM5	M58R

TM5	V537A

TM5	F465Y, S733L

TM5	F465Y, G471S

TM5	K488R

TM5, TM9

TM8

TM10

TM10

ICH5	N723I

ICH5	V404G

	V473G, D611G, I626V

	G103S, F111L


		Humanities and social sciences	%	Natural and formal sciences	%	Applied sciences and professions	%

University category	Highest research	149	50	75	47	112	33

	Higher research	113	38	54	34	146	42

	Moderate research	37	12	31	19	86	25

	Total	299	100	160	100	344	100

Tenure	Yes	215	72	108	68	244	71

	No	69	23	42	26	76	22

	N/A	15	5	10	6	24	7

	Total	299	100	160	100	344	100

Rank	Lecturer	6	2	4	3	8	2

	Adjunct	2	1	1	1	4	1

	Assistant	57	19	33	21	60	17

	Associate	100	33	37	23	92	27

	Full	92	31	66	41	147	43

	University	12	4	6	4	6	2

	Emeritus	18	6	4	3	12	3

	Other	12	4	9	6	15	4

	Total	299	100	160	100	344	100

Gender	Male	156	52	114	71	177	51

	Female	143	48	46	29	167	49

	Total	299	100	160	100	344	100


	H2-Db	H2-Kb	H2-Kk

	Additive Method	SVRMHC Method	Additive Method	SVRMHC Method	Additive Method	SVRMHC Method

Numbers of outliers	6	3	7	6	2	0

r2 (self-consistency, outliers removed)	0.946	0.983	0.989	0.97	0.933	0.973

r2 (self-consistency, entire dataset)	0.602	0.749	0.37	0.568	0.849	0.973

Average Residual (entire dataset)	0.403	0.17	0.443	0.382	0.178	0.039

Average Residual (outliers removed)	0.187	0.043	0.095	0.13	0.151	0.039

q2 (LOO_CV) (outliers removed)	0.401	0.456	0.454	0.486	0.456	0.721

	H2-Db	H2-Kb	H2-Kk

	Additive Method	SVRMHC Method	Additive Method	SVRMHC Method	Additive Method	SVRMHC Method

Average Residual (entire dataset)	0.403	0.17	0.443	0.382	0.178	0.039

Average Residual (outliers removed)	0.187	0.043	0.095	0.13	0.151	0.039

q2 (LOO_CV) (outliers removed)	0.401	0.456	0.454	0.486	0.456	0.721


Striatal region	Reward scan	Expectation scan	No-drug scan

Early	Late	Early	Late	Early	Late

Right	1.91 ± 0.29	1.90 ± 0.22	1.90 ± 0.26	1.90 ± 0.28	1.99 ± 0.32	2.01 ± 0.25


Strain1	Genbank accession #	Experiment location	Strawberry tissue	Closest sequence relatives

Strain(s)	Genbank accession #	Homology %

G1	JN636809	greenhouse	leaf	Candida sp. GA1S07	FJ527144	98

G2*	JN636810	greenhouse	leaf	Cryptococcus sp. VTT C-04547	DQ377668	100

G3	JN636811	greenhouse	leaf	Sakaguchia dacryoidea CBS 6353	AF189973	94

G4	JN636812	greenhouse	leaf	Cryptococcus sp. KCTC 17100	AF459675	100

G5*	JN636813	greenhouse	leaf	Sporobolomyces sp. KCTC 17098	AF459715	95

F1*	JN636806	field	leaf	Cryptococcus sp. HB 982	FM242574	99

F2	JN636807	field	leaf	Cryptococcus heveanensis YFL1.1	HQ629577	99

F3	JN636808	field	ripe fruit	Rhodotorula graminis WP1	EU563930	99

F4*	JN636804	field	unripe fruit	Pichia guilliermondii SYHZS-1	EU809436	100

F5*	JN636805	field	unripe fruit	Metschnikowia pulcherrima Afen	EU272042	95


Watermelon source	Cultivar	(Glucose)(%, w/v)	(Fructose)(%, w/v)	(Sucrose)(%, w/v)	(Amino N)μmol/ml)	(Citrulline)μmol/ml)

2007 Hinton, OK, USA	Crunchy Red	1.4	2.8	3.0	16.3	6.3

2007 Terral, OK, USA	Unknown	2.0	3.6	2.0	33.6	15.4

2008 Louisiana, USA	Summer Flavor 800	1.9	3.5	2.8	33.9	12.6

2008 Lane, OK, USA	Sangria	1.9	3.6	2.8	17.7	5.8

2008 Lane, OK, USA	Dixie Lee	1.7	3.1	1.8	19.9	3.7

Watermelon source	Cultivar	(Glucose)(%, w/v)	(Fructose)(%, w/v)	(Sucrose)(%, w/v)	(Amino N)μmol/ml)	(Citrulline)μmol/ml)

2007 Terral, OK, USA	Unknown	2.0	3.6	2.0	33.6	15.4

2008 Louisiana, USA	Summer Flavor 800	1.9	3.5	2.8	33.9	12.6

2008 Lane, OK, USA	Sangria	1.9	3.6	2.8	17.7	5.8

2008 Lane, OK, USA	Dixie Lee	1.7	3.1	1.8	19.9	3.7


Oxidative Stress Genes	Average ΔCt	2 ^ -Δ Ct	Fold Expression

	+DOX	−DOX	+DOX	−DOX	+DOX/− DOX

glutathioneperoxidase2 (GPX2)	8.68	7.06	2.4E-03	7.5E-03	−3.07

peroxidasin (PXDNL)	12.48	10.16	1.8E-04	8.7E-04	−4.99

sulfiredoxin (SRXN1)	6.08	5.06	1.5E-02	3.0E-02	−2.03

peroxiredoxin 2 (PRDX2)	1.68	0.96	3.1E-01	5.1E-01	−1.65

COX2	4.78	4.06	3.6E-02	6.0E-02	−1.65

arachidonate 12-lipoxygenase (12-LOX)	10.08	9.36	9.2E-04	1.5E-03	−1.65

superoxide dismutase 2 (SOD2)	1.08	0.56	4.7E-01	6.8E-01	−1.43*

superoxide dismutase 3 (SOD3)	4.68	4.16	3.9E-02	5.6E-02	−1.43*


Study	Input number	Baseline (%)	FNN	Accuracy (%)	number of subject	Input characteristic

 	 	 	 	multiple linear regression	multiple logistic regression	Case	Healthy control	1 input	2 inputs

Original Study	1 input	63.46	73.88	69.23	73.72	57	99	γ-GTP (IU/L)	−

 	2 inputs	63.71	77.43	75.81	75.81	45	79	γ-GTP (IU/L)	WBC (cells/μL)

Replication Study	1 input	50.00	64.96	64.18	66.44	2196	2196	γ-GTP (IU/L)	−

 	2 inputs	50.00	67.14	66.10	68.53	2196	2196	γ-GTP (IU/L)	WBC (cells/μL)


	Primary aldosteronism N = 158

Source	F statistic	p-value

Age	0.28	0.598

Sex	13.15	<0.001

Hypertension duration	1.98	0.162

Mean blood pressure	5.78	0.018

UAldo, tertile	6.11	0.003

UNa, tertile	7.29	0.001

UAldo*UNa	0.25	0.907


Plant species	Origin	uPA inhibitoryactivity *

Amyris elemifera	Florida, Bahamas, Puerto Rico, West Indies, Central America.	+

Bidens alba L.	Native to South America. Pan tropical weed	−

Cananga odorata	Native to southern Asia and Philippines	+

Capparis cynophallophora	Florida, Bahamas, Puerto Rico, West Indies, Central America.	−

Colubrina elliptica	Puerto Rico, Florida, Bahamas, West Indies, Central Mexico to Venezuela	−

Croton lucidus	Native to PR, Bahamas, Greater Antilles, and Grand Cayman.	+

Erythroxylum areolatum	Bahamas, Greater Antilles, and South America	+

Exostema caribaeum	Florida, Bahamas, West Indies, Mexico, Central America, NE coast South America	−

Guaiacum officinale	Continental Tropical America, PR, West Indies	−

Kalanchoe pinnata	Native to Madagascar	−

Lantana camara	Pantropical	+

Plumeria alba L.	Central America and the Caribbean	−

Tabebuia heterophylla	Puerto Rico, Hispaniola, Virgin Islands, and Lesser Antilles.	+

Vanilla claviculata	Puerto Rico and Greater Antilles	−

Plant species	Origin

Amyris elemifera	Florida, Bahamas, Puerto Rico, West Indies, Central America.

Bidens alba L.	Native to South America. Pan tropical weed

Cananga odorata	Native to southern Asia and Philippines

Capparis cynophallophora	Florida, Bahamas, Puerto Rico, West Indies, Central America.

Colubrina elliptica	Puerto Rico, Florida, Bahamas, West Indies, Central Mexico to Venezuela

Croton lucidus	Native to PR, Bahamas, Greater Antilles, and Grand Cayman.

Erythroxylum areolatum	Bahamas, Greater Antilles, and South America

Exostema caribaeum	Florida, Bahamas, West Indies, Mexico, Central America, NE coast South America

Guaiacum officinale	Continental Tropical America, PR, West Indies

Kalanchoe pinnata	Native to Madagascar

Lantana camara	Pantropical

Plumeria alba L.	Central America and the Caribbean

Tabebuia heterophylla	Puerto Rico, Hispaniola, Virgin Islands, and Lesser Antilles.

Vanilla claviculata	Puerto Rico and Greater Antilles

uPA inhibitoryactivity *

+

−

+

−

−

+

+

−

−

−

+

−

+

−


GO attribute	No. of genes in category	No. of genes bound by Gcn5p (P value)	No. of genes bound by Sas3p (P value)	No. of genes bound by both (P value)

Cytosolic ribosome	171	43 (3.6 × 10-26)	54 (3.2 × 10-29)	17 (9.4 × 10-16)

Ribosome	284	51 (1.1 × 10-23)	67 (8.6 × 10-28)	21 (6.8 × 10-16)


Variable

GENDER

Male

Female

AGE

65–74

75–84

> 84

SCHOOLING

< primary

≥primary

MARITAL STATUS

Single

Married

Widowed

Divorced

HOSPITALIZATION TIME

< 1 year

1–5 years

>5 years

AMOUNT RECEIVED BY THE OWNER OF SOCIAL SECURITY

<€445

≥€445

STATE SEVERITY BIMS

Intact cognition

Moderate

Severe


Gene	#	A	B	C	Gene description	Accession numbers

Symbols	Mean	SD	Mean	SD	Mean	SD

hsp90+	8	5.03*	0.79	0.20*	0.16	0.79	0.15	Heat shock protein 90. beta	NM_198210

fas+	9	4.09*	0.27	0.61*	0.09	1.27	0.16	Fas (TNF receptor superfamily, member 6)	XM_685355

il1b	14	3.71*	0.47	0.42*	0.05	2.05*	0.34	Interleukin 1, beta	NM_212844

hspb+	7	3.51*	0.33	0.52*	0.04	2.27*	0.32	Heat shock protein. alpha-crystalline-related	NM 001008615

Ifih	7	2.78*	0.47	0.48*	0.02	0.78	0.04	Novel protein similar to vertebrate interferon	XM_689032

irf7	8	2.65*	0.17	0.80	0.05	1.29	0.16	Interferon regulatory factor 7	NM_200677

faslg+	11	2.38*	0.28	0.84	0.05	0.91	0.26	Fas ligand (TNF superfamily, member 6)	NM_001042701

casp7+	7	2.23*	0.07	0.55*	0.04	1.36	0.11	Caspase 7, apoptosis cysteine peptidase	NM_001020607

jak1	17	2.21*	0.14	0.76	0.07	1.25	0.12	Janus kinase 1	NM_131073

stat3	13	2.17*	0.24	0.80	0.10	1.18	0.07	Signal transduction/activation transcription 3	XM_002661113

stat1a	23	1.93*	0.15	1.00	0.18	1.21	0.17	Signal transduction/activation transcription 1a	NM_131480

Ikbke	9	1.90*	0.12	0.69	0.03	1.65	0.19	Inhibitor of kappa light polypeptide gene	NM_001002751

Tnfsf	8	1.82*	0.54	0.73	0.21	1.16	0.39	Tumor necrosis factor (ligand) superfamily	NM_001002593

inpp5d	7	1.75*	0.11	0.79	0.01	1.09	0.08	Inositol polyphosphate-5-phosphatase	XM_001922972

irf6	8	0.73	0.12	0.90	0.29	2.15*	0.56	Interferon regulatory factor 6	NM_200598

Igm	7	0.03*	0.01	0.73	0.04	0.51*	0.02	Ig heavy chain constant region home design	AY643753

Gene	#	A	B	C	Gene description	Accession numbers

Symbols	Mean	SD	Mean	SD	Mean	SD

jak1	17	2.21*	0.14	0.76	0.07	1.25	0.12	Janus kinase 1	NM_131073

stat3	13	2.17*	0.24	0.80	0.10	1.18	0.07	Signal transduction/activation transcription 3	XM_002661113

stat1a	23	1.93*	0.15	1.00	0.18	1.21	0.17	Signal transduction/activation transcription 1a	NM_131480

Ikbke	9	1.90*	0.12	0.69	0.03	1.65	0.19	Inhibitor of kappa light polypeptide gene	NM_001002751

Tnfsf	8	1.82*	0.54	0.73	0.21	1.16	0.39	Tumor necrosis factor (ligand) superfamily	NM_001002593

inpp5d	7	1.75*	0.11	0.79	0.01	1.09	0.08	Inositol polyphosphate-5-phosphatase	XM_001922972

irf6	8	0.73	0.12	0.90	0.29	2.15*	0.56	Interferon regulatory factor 6	NM_200598

Igm	7	0.03*	0.01	0.73	0.04	0.51*	0.02	Ig heavy chain constant region home design	AY643753


Patients demographics	N, % (total 30)

Age (mean, SD)	35.6 (9.3)

Gender

 Males	6 (20.0)

 Females	24 (80.0)

Pre-op BMI (mean, SD)	42.8 (5.8)

Diabetes	4 (13.3)

History of smoking	4 (13.3)

Type of bariatric surgery

 Sleeve gastrectomy RYG bypass	28 (93.3)

2 (6.7)

Patients demographics

Age (mean, SD)

Gender

Males

Females

Pre-op BMI (mean, SD)

Diabetes

History of smoking

Type of bariatric surgery

Sleeve gastrectomy RYG bypass


		Significancea

Valence	Percentage	Race/Ethnicity	Gender	Age	Education

Negative	80%	–	–	–	–

Ambivalent or Neutral	30%	*	+	–	–

Positive	59%	–	–	–	–

Not discernible	52%	–	–	–	–

		Significancea

Valence	Percentage	Race/Ethnicity	Gender	Age	Education

N	80%		–		–

egative		–		–

Ambivalent or Neutral	30%	*	+	–	–

Positive	59%	–	–	–	–

Not discernible	52%	–	–	–	–


Ingredient:	%

Corn	59.36

SBM, dehulled (48% CP)	33.70

Corn Oil	3.00

Dicalcium phosphate (Technical grade)	1.47

Calcium carbonate (Technical grade)	1.21

Salt, iodized	0.45

DL-methionine	0.21

L-lysine	0.10

Vitamin premix1 (no mineral)	0.25

Mineral premix2 (no Zn)	0.25

Total	100.00

<underline>Calculated (analyzed) nutrients</underline>

ME, kcal/kg	3,080

CP, %	21

Ca3, %	1.00 (1.3)

Nonphytate P3, %	0.45 (0.40)

Lysine, %	1.24

Methionine + Cystein, %	0.90

Zinc (mg/kg)	25

Dicalcium phosphate (Technical grade)	1.47

Calcium carbonate (Technical grade)	1.21

Salt, iodized	0.45

DL-methionine	0.21

L-lysine	0.10

Vitamin premix1 (no mineral)	0.25

Mineral premix2 (no Zn)	0.25

Total	100.00

Calculated (analyzed) nutrients

ME, kcal/kg	3,080

CP, %	21

Ca3, %	1.00 (1.3)

Nonphytate P3, %	0.45 (0.40)

Lysine, %	1.24

Methionine + Cystein, %	0.90

Zinc (mg/kg)	25


Substrate	Dyad position	Translational shift

 	 	(base pairsa)

S1	74	-

S1-CGG19	72	−2

S1-1AGGa	74.75	+0.75

S1-1AGGb	77.5	+3.5

S1-2AGG	78	+4

Substrate	Dyad position	Translational shift

		(base pairsa)

S1-CGG19	72	−2

S1-1AGGa	74.75	+0.75

S1-1AGGb	77.5	+3.5

S1-2AGG	78	+4


Gene or Construct	Accession No:	Primers	Template	Vector

NvStbm (in situ hybridization probe)	1526895:4	Forward 5' CGACAAAGCGAACCAATGTTTACTCT 3'Reverse 5' CCGACATCATGTAAGGGTTATACTCA 3'	Mixed stage N.vectensis cDNA	pGEM

NvStbm (Full-length)	1526895:4	Forward 5'GCCGGAATTCATGCCGCAATATCGTACCAAAGAC 3'Reverse 5' GCCTAGGCCTGACGGAGGTCTCCGAATTTAACTTG 3'	Mixed stage N.vectensis cDNA	pCS2+GFP

NvFz10	XP_001630630	Forward 5' AGTACGATCAGTGCGTCCCCCAATG 3'Reverse 5' CCGCCACGACTTGAATGTTTTTGTAG 3'	Mixed stage N.vectensis cDNA	pGEM

NvFz5	XP_001634995	Forward 5' GCGAAGAGATCACCATTCCCATGTGC 3'Reverse 5' ACCCACCAAACAGAGGAAGCCATTC 3'	Mixed stage N.vectensis cDNA	pGEM

SpAxin	XP_781992	Forward 5' GCCGGAATTCATGAGTCTAGAAGTGTATAGGTTC 3'Reverse 5' GCCGAGGCCTGTGATCATCGACAGATTCCACCTG 3'	Blastula stage S. purpuratus cDNA	pCS2+GFP

Gene or Construct	Accession No:	Primers	Template	Vector

NvFz10	XP_001630630	Forward 5' AGTACGATCAGTGCGTCCCCCAATG 3'Reverse 5' CCGCCACGACTTGAATGTTTTTGTAG 3'	Mixed stage N.vectensis cDNA	pGEM

NvFz5	XP_001634995	Forward 5' GCGAAGAGATCACCATTCCCATGTGC 3'Reverse 5' ACCCACCAAACAGAGGAAGCCATTC 3'	Mixed stage N.vectensis cDNA	pGEM

SpAxin	XP_781992	Forward 5' GCCGGAATTCATGAGTCTAGAAGTGTATAGGTTC 3'Reverse 5' GCCGAGGCCTGTGATCATCGACAGATTCCACCTG 3'	Blastula stage S. purpuratus cDNA	pCS2+GFP


Gd-dendrimer generation (G)	Peak concentration in orthotopic RG-2 gliomas (mM)	Peak concentration time point (min)	Peak concentration in ectopic RG-2 gliomas (mM)	Peak concentration time point (min)

Gd-G5	0.147	167	0.195	149

Gd-G6	0.106	200	0.144	189

Gd-G7	0.064	75	0.084	107

Gd-G8	0.049	77	0.052	81

Gd-dendrimer generation (G)	Peak concentration in orthotopic RG-2 gliomas (mM)	Peak concentration time point (min)	Peak concentration in ectopic RG-2 gliomas (mM)	Peak concentration time point (min)

Gd-G7	0.064	75	0.084	107

Gd-G8	0.049	77	0.052	81


	DVT(n = 9)	PE(n = 9)	AF(n = 13)	Total(n = 31)

COUNTRY (n)

France	3	3	5	11

The Netherlands	3	3	4	10

The United States	3	3	4	10

GENDER (n)

Male	5	2	7	14

Female	4	7	6	17

AGE (years)

Range	21 – 77	30 – 74	39 – 79	21 – 79

Mean	47.4	51.3	68.5	57.4

LIVING SITUATION (n)

Living alone	3	.	5	8

Living as a couple	6	9	8	23

LEVEL OF EDUCATION (n)

Primary school	1	.	3	4

High school diploma	3	3	3	9

Some college or vocational school	1	3	4	8

College or university degree	3	2	1	6

Graduate or professional school	1	1	1	3

Other, please specify	.	.	1 (grammar school)	1

EMPLOYMENT STATUS (n)

Full-time paid employment	4	1	1	6

Part-time paid employment	1*	1*	1	3

Homemaker/housewife	.	1	1	2

Retired	3	3	10	16

Unemployed	.	1	.	1

Not working due to present health status	.	2	.	2

Other, please specify	1 (disabled)	.	.	1

COUNTRY (n)

France

The Netherlands

The United States

GENDER (n)

Male

Female

AGE (years)

Range

Mean

LIVING SITUATION (n)

Living alone

Living as a couple

LEVEL OF EDUCATION (n)

Primary school

High school diploma

Some college or vocational school

College or university degree

Graduate or professional school

Other, please specify

EMPLOYMENT STATUS (n)

Full-time paid employment

Part-time paid employment

Homemaker/housewife

Retired

Unemployed

Not working due to present health status

Other, please specify


Neurological status	n	Canal compromise (%)	Loss of vertebral body height (%)	kyphotic angle (degree)

A	11	52.27 ± 9.73	42.18 ± 8.36	15.27 ± 4.00

B	16	50.38 ± 8.65	38.06 ± 12.34	15.75 ± 6.87


Group			Very low	Low	Moderate	High

	M		N				N			%


Regions	L/R	MNI (X, Y, Z)	Voxels (mm3)	t-Score

Thalamus	R	14, -30, 10	28	2.9962

Thalamus	L	-12, -28, 9	35	3.6621

Posterior cingulate	R	-13, -50, 16	31	3.5521

Posterior cingulate	L	12, -45, 18	28	2.7536

Angular gyrus	L	-56, -47, 39	35	3.8926

Inferior parietal lobule	L	-50, -27, 25	28	3.6249

Regions	L/R	MNI (X, Y, Z)	Voxels (mm3)	t-Score

Thala	R	14, -3


GO:BP terms enriched in orthologs differentially expressed exclusively in C. elegans

GO.ID	Term	Annotated	Significant	Expected	p-Value

GO:0018996	molting cycle; collagen and cuticulin-based cuticle.	157	17	4.19	5.70E-07

GO:0040011	locomotion	789	34	21.07	0.0019

GO:0040018	positive regulation of multicellular organism growth	167	11	4.46	0.0046

GO:0006560	proline metabolic process	5	2	0.13	0.0067

GO:0010171	body morphogenesis	322	16	8.6	0.0106

GO:0009084	glutamine family amino acid biosynthesis	8	2	0.21	0.0178

GO:0006694	steroid biosynthetic process	10	2	0.27	0.0277

GO:0055114	oxidation-reduction process	219	11	5.85	0.0306

GO:0006508	proteolysis	197	10	5.26	0.0362

GO:0018991	oviposition	145	8	3.87	0.0387

GO:MF terms enriched in orthologs differentially expressed exclusively in C. elegans

GO.ID	Term	Annotated	Significant	Expected	p-Value

GO:0042302	structural constituent of cuticle	21	10	0.53	1.60E-11

GO:0004222	metalloendopeptidase activity	50	6	1.25	0.0014

GO:0016776	phosphotransferase activity; phosphate group as acceptor	5	2	0.13	0.0059

GO:0016903	oxidoreductase activity; acting on the aldehyde or oxo group of donors	8	2	0.2	0.0157

GO:0003854	3-beta-hydroxy-delta5-steroid dehydrogenase activity	8	2	0.2	0.0157

GO:0019205	nucleobase; nucleoside; nucleotide kinase activity	8	2	0.2	0.0157

GO:0020037	heme binding	51	4	1.28	0.0374

GO:0004601	peroxidase activity	14	2	0.35	0.0464

GO:BP terms enriched in orthologs differentially expressed exclusively in C. elegans

GO.ID	Term	Annotated	Significant	Expected	p-Value

GO:0019205	nucleobase; nucleoside; nucleotide kinase activity	8	2	0.2	0.0157

GO:0020037	heme binding	51	4	1.28	0.0374

GO:0004601	peroxidase activity	14	2	0.35	0.0464